



Europäisches
Patentamt
European
Patent Office
Office européen
des brevets

[EPD 18 MY KIM +100p]

URKUNDE

Europäisches Patent

Es wird hiermit bescheinigt,
dass für die in der Patentschrift
beschriebene Erfindung ein
europäisches Patent für die in
der Patentschrift bezeichneten
Vertragsstaaten erteilt worden ist.

Europäisches Patent Nr.
European patent No.
Brevet européen n°

Patentinhaber
Proprietor(s) of the patent
Titulaire(s) du brevet

CERTIFICATE

European patent

It is hereby certified that a
European patent has been granted
in respect of the invention
described in the patent specifica-
tion for the Contracting States
designated in the specification.

3045529

INSTITUT PASTEUR DE LILLE
1, rue du Professeur Calmette
59000 Lille/FR

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE
MEDICALE
101, Rue de Tolbiac
75654 Paris Cedex 13/FR

CERTIFICAT

Brevet européen

Il est certifié qu'un brevet
européen a été délivré pour
l'invention décrite dans le
fascicule de brevet, pour les
Etats contractants désignés
dans le fascicule de brevet.

António Campinos

Präsident des Europäischen Patentamts
President of the European Patent Office
Président de l'Office européen des brevets

München, den
Munich,
Munich, le

29.07.20

(19)



(11)

EP 3 045 529 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
29.07.2020 Bulletin 2020/31

(51) Int Cl.:
C12N 1/36 (2006.01) **A61K 39/10 (2006.01)**
A61K 39/02 (2006.01) **A61K 39/00 (2006.01)**

(21) Application number: **16155296.3**

(22) Date of filing: **07.03.2007**

(54) LIVE ATTENUATED BORDETELLA STRAINS AS A SINGLE DOSE VACCINE AGAINST WHOOPING COUGH

LEBENDE ABGESCHWÄCHTE BORDETELLASTÄMME ALS EINZELDOSISIMPFSTOFF GEGEN KEUCHHUSTEN

SOUCHES VIVANTES ATTÉNUÉES DE BORDETELLA EN TANT QUE VACCIN UNIDOSE CONTRE LA COQUELUCHE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

(30) Priority: **10.03.2006 US 780827 P**
30.06.2006 US 817430 P

(43) Date of publication of application:
20.07.2016 Bulletin 2016/29

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
07711815.6 / 1 994 139

(73) Proprietors:
• **INSTITUT PASTEUR DE LILLE**
59000 Lille (FR)
• **INSTITUT NATIONAL DE LA SANTE ET DE LA**
RECHERCHE
MEDICALE
75654 Paris Cedex 13 (FR)

(72) Inventors:
• **LOCHT, Camille**
1180 Bruxelles (BE)
• **MIELCAREK, Nathalie**
7522 Blandain (BE)
• **DEBRIE, Anne-Sophie**
59110 La Madeleine (FR)
• **RAZE, Dominique**
59152 Gruson (BE)
• **BERTOUT, Julie**
59710 Pont-à-Marcq (FR)

(74) Representative: **Grosset-Fournier, Chantal**
Catherine et al
Grosset-Fournier & Demachy
54, rue Saint-Lazare
75009 Paris (FR)

(56) References cited:
WO-A1-03/102170

- **MATTOO S ET AL: "Mechanisms of Bordetella pathogenesis.", FRONTIERS IN BIOSCIENCE : A JOURNAL AND VIRTUAL LIBRARY 1 NOV 2001, vol. 6, 1 November 2001 (2001-11-01), pages E168-E186, XP008065245, ISSN: 1093-4715**
- **MATTOO SEEMA ET AL: "Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.", CLINICAL MICROBIOLOGY REVIEWS APR 2005, vol. 18, no. 2, April 2005 (2005-04), pages 326-382, XP002443068, ISSN: 0893-8512**
- **LOCHT C ET AL: "Bordetella pertussis: from functional genomics to intranasal vaccination", INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, URBAN UND FISCHER, DE, vol. 293, no. 7-8, 2004, pages 583-588, XP004959965, ISSN: 1438-4221**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 045 529 B1

- NATHALIE MIELCAREK ET AL: "Live Attenuated B. pertussis as a Single-Dose Nasal Vaccine against Whooping Cough", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 2, no. 7 e65, 1 July 2006 (2006-07-01), pages 662-670, XP007909792, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.0020065
- PASCAL FEUNOU FEUNOU ET AL: "T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis", PLOS ONE, vol. 5, no. 4, 1 January 2010 (2010-01-01), pages 1-10, XP55004504, US ISSN: 1932-6203, DOI: 10.1371/journal.pone.0010178
- FEUNOU P F ET AL: "Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 43, 8 October 2010 (2010-10-08), pages 7047-7053, XP027392055, ISSN: 0264-410X [retrieved on 2010-08-13]
- FEUNOU P F ET AL: "Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 45, 23 October 2008 (2008-10-23), pages 5722-5727, XP026046068, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2008.08.018 [retrieved on 2008-08-30]
- W. BURNETTE ET AL: "Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope", SCIENCE, vol. 242, no. 4875, 7 October 1988 (1988-10-07), pages 72-74, XP055550020, US ISSN: 0036-8075, DOI: 10.1126/science.2459776

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

Field of the Invention

[0001] The present invention relates to a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene and a heterologous *ampG* gene. The attenuated mutated *Bordetella* strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a *Bordetella* infection. Use of the attenuated *Bordetella* strain for the manufacture of a vaccine or immunogenic compositions, as well as methods for protecting mammals against infection by *Bordetella* also form a part of the invention.

Background of the Invention and Related Prior Art

[0002] *Pertussis* is still among the principal causes of death world-wide, and its incidence is increasing even in countries with high vaccine coverage. Although all age groups are susceptible, it is most severe in infants too young to be protected by currently available vaccines.

[0003] Whooping cough or *pertussis* is a severe childhood disease responsible for high mortality rates before the introduction of effective vaccines in the second half of the 20th century. The success of these vaccines has led to the opinion that the disease is essentially under control, although world-wide 200,000 to 400,000 *pertussis*-linked deaths are still recorded annually, and the disease still ranks sixth among the causes of mortality due to infectious agents [1]. Although mostly prevalent in developing countries, the disease is also re-emerging in the developed world [2, 3], including the U.S.A., where the incidence has increased five-fold over the last twenty years [4]. Unexpectedly, the epidemiology of *pertussis* has changed in countries with high vaccine coverage, where cases of adolescent and adult *pertussis* are increasingly frequent [5]. This is probably due to progressive waning of vaccine-mediated immunity during adolescence. Often atypical and therefore difficult to diagnose, *pertussis* is generally not life-threatening in adults and in many cases remains unnoticed. However, infected adults constitute an important reservoir for transmission of the disease to very young children, too young to be fully vaccinated, and therefore at risk to develop severe disease associated with high mortality rates.

[0004] *Pertussis* vaccination usually begins at two months of age, and full protection requires at least three immunizations at one- to two-month intervals. Therefore, infants are not fully protected before the age of 6 months using the currently available vaccines. To reduce the incidence of *pertussis* in the very young and most vulnerable age groups, early immunization, possibly at birth, would thus be highly desirable. However, numerous studies in humans and in animal models have suggested that the neonatal immune system is too immature to effectively induce vaccine-mediated protective immunity [6, 7]. Especially the IFN- γ production, indicative of a Th1 response that is essential to the development of protective immunity to *pertussis* [8], appears to be significantly reduced in human newborns, compared to older children or adults [9]. This is also reflected by the fact that significant amounts of antigen-specific IFN- γ are only produced after several months (≥ 6 months) in children vaccinated with *pertussis* vaccines, especially with acellular vaccines (aPV) [10].

[0005] Natural infection with *Bordetella pertussis* has long been considered to induce strong and long-lasting immunity, that wanes much later than vaccine-induced immunity [5, 11]. Furthermore, infection with *B. pertussis* induces measurable antigen-specific Th1 type immune responses even in very young children (as young as one month of age) [12]. These observations suggest that live vaccines applicable by the nasal route in order to mimic as closely as possible natural infection, may be attractive alternatives over the currently available vaccines.

[0006] There are many vaccinating compositions to treat *Bordetella* infections known in the art. However, these immunogenic compositions are not used to treat newborn children or in cases where an epidemic and rapid protective immunity is required.

[0007] Thus, French Patent FR 0206666 discloses live *Bordetella* strains that have been rendered deficient in at least two toxins chosen from PTX, DNT, AC and TCT. This patent discloses the over expression of an endogenous *ampG* gene by the addition of a strong promoter, and the addition of 11 terminal amino acids of the *ampG* gene from *E. coli*.

[0008] Mielcarek et al, Vaccine (2006; 24S2: S2/S4-S2/S5) disclose a strain of *Bordetella pertussis* attenuated of PTX⁻, DTN⁻ and TCT⁻ for use in the immunization of mice. This reference discloses that to reduce the production of tracheal cytotoxin, the *ampG* gene should be overexpressed. However, upon further evaluation, the authors realized that by over-expressing the *ampG* gene, there is an increase in tracheal cytotoxin and not a decrease as was originally thought.

[0009] Mielcarek et al in Advance Drug Delivery Review 51 (2001) pgs. 55-69 disclose that live vaccines can induce systemic and mucosal responses when administered by the oral or nasal route.

[0010] Roduit et al in Infection and Immunity (2002 Jul; 70(7): 3521-8) describe vaccinating neonatals and infants with mutated *Bordetella* strains with a DTP composition.

[0011] Mattoo et al, in Frontiers of Bioscience 6, e168-e186 (2001), suggest replacing the endogenous *ampG* gene in *Bordetella* with the *E. coli ampG* gene, which resulted in a decrease in the amount of TCT produced.

[0012] Thus, the prior art although disclosing various types of vaccinating compositions fails to address the problem

of providing a vaccine or immunogenic composition that can provide protection to a newborn prior to six months. Furthermore, the prior art fails to disclose an immunogenic or a vaccine that provides rapid protective immunity against a *Bordetella* infection. The prior art also fails to disclose an immunogenic composition or vaccine that provides a rapid protective immunity against a *Bordetella* infection, said protective immunity increasing over at least the next two months following vaccination.

[0013] Therefore, it is an object of the present invention to overcome the deficiencies in the prior art.

[0014] It is another object of the present invention to produce a live attenuated vaccine candidate or immunogenic composition through genetic attenuation of a *Bordetella* strain such as *B. pertussis* or *B. parapertussis* to diminish pathogenicity, while maintaining the ability to colonize and induce protective immunity.

[0015] It is another object of the present invention to produce a vaccine or immunogenic composition that induces protection in newborns after a single intranasal administration that is superior to the protection provided by the current aPV.

[0016] It is yet another object of the present invention to provide protection against infection with *Bordetella parapertussis*, as well as *Bordetella pertussis* which was not seen after vaccination with aPV.

[0017] Another object of the present invention is to induce strong protective immunity in newborns against *Bordetella* infection.

[0018] Yet another object of the present invention is to provide a vaccine or immunogenic composition that induces mucosal and systemic immunity.

[0019] It is another object of the present invention to produce a live attenuated *Bordetella pertussis* strain to be given as a single-dose nasal vaccine in early life, called BPZE1.

[0020] It is yet another object of the present invention to provide a vaccine that can not only be used to vaccinate newborns, but can be used in all mammals of any age in the case of an epidemic of whooping cough.

[0021] Another object of the present invention is to provide a vaccine against *Bordetella* infection that induces a rapid protective immunity and/or a protective immunity that increases over at least the next two months after the vaccination.

[0022] Yet another object of the present invention is to provide prevention or treatment against *Bordetella* infection that is relatively low in production costs.

[0023] These and other objects are achieved by the present invention as evidenced by the summary of the invention, description of the preferred embodiments and the claims.

Summary of the Invention

[0024] The invention is defined in the appended claims and any other aspects or embodiments set forth herein are for information only.

[0025] The present invention provides a mutated *Bordetella* strain comprising at least a mutated *pertussis* toxin (*ptx*) gene, a deleted or mutated dermonecrotic toxin (*dnt*) gene, and a heterologous *ampG* gene.

[0026] In another aspect the present invention relates to an immunogenic composition comprising a mutated *Bordetella* strain comprising at least a mutated *pertussis* toxin (*ptx*) gene, a deleted or mutated *pertussis* dermonecrotic toxin (*dnt*) gene, and a heterologous *ampG* gene.

[0027] In yet another aspect the present invention provides a vaccine comprising the attenuated *Bordetella* strain comprising at least a mutated *pertussis* toxin (*ptx*) gene, a deleted or mutated *pertussis* dermonecrotic toxin (*dnt*) gene, and a heterologous *ampG* gene.

[0028] It still another aspect, the present invention provides the use of an attenuated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene for the manufacture of a vaccine for the prevention of a *Bordetella* infection.

[0029] In yet another aspect, the present invention provides the use of an attenuated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene for the manufacture of a vaccine for the induction of an immune response directed preferentially toward the Th1 pathway against said attenuated *Bordetella*.

[0030] Also provided is a method of protecting a mammal against disease caused by infection by *Bordetella pertussis* and *Bordetella parapertussis* comprising administering to said mammal in need of such treatment a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene.

[0031] A method of providing a rapid protective immunity against a *Bordetella* infection comprising administering to said mammal in need of such treatment a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene is also part of the present invention.

[0032] A method of providing a rapid protective immunity against a *Bordetella* infection comprising administering to a mammal in need of such treatment a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene or a vaccine comprising said mutated *Bordetella* strain, wherein said method provides further an increase in said protective immunity over at least two months after vaccination is still another aspect of the present invention.

[0033] Use of the mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene and a heterologous *ampG* gene for the preparation of a multivalent vaccine (*i.e.*, a vaccine for preventing or treating infections caused by different pathogens) to treat respiratory diseases is yet another aspect of the present invention.

[0034] Use of an attenuated *Bordetella* strain of the invention, by administration to mammals in need of a rapid protective immunity against a *Bordetella* infection, wherein said protective immunity increases over at least two months after administration, is also part of the present invention.

[0035] A method to provide a mucosal response and a systemic response to treat or protect against *Bordetella* infections in mammals is still another aspect of the present invention.

Brief Description of the Drawings

[0036]

Fig. 1 is a bar graph illustrating the TCT present in culture supernatants of BPSM and BPZE1 expressed as means of nM/OD_{540nm} (\pm standard error) of 3 separate cultures for each strain.

Fig. 2 is an immunoblot analysis of PTX production in the culture supernatants of BPSM (lane 1) and BPZE1 (lane 2). The sizes of the Mr markers are expressed in kDa and given in the left margin.

Fig. 3 is a Southern-blot analysis of the *dnt* locus in BPSM (lane 1) and BPZE1 (lane 2). The lengths of the size markers are indicated in base pairs (bp) are shown in the left margin.

Fig. 4 is a graph illustrating the growth rates of BPSM (black line) and BPZE1 (dotted line) in liquid culture.

Fig. 5 are electron micrographs representative of BPSM (left) and BPZE1 (right) grown in liquid medium for 24 h.

Fig. 6 is a graph illustrating the *in vitro* adherence of BPSM (black columns) and BPZE1 (white columns) to human pulmonary epithelial A549 cells (left) and murine macrophage-like J774 cells (right). The results are expressed as means of percentages of binding bacteria relative to the bacteria present in the inoculum from three different experiments.

Fig. 7 is a graph illustrating lung colonization by BPSM (black lines) and BPZE1 (dotted lines) of adult mice infected intranasally with 10⁶ CFU of BPZE1 or BPSM. The results are expressed as mean (\pm standard error) CFUs from three to four mice per group and are representative of two separate experiments. *, *P* = 0.004.

Fig. 8 are photographs of a histological analysis of lungs from BPZE1 (upper panel) or BPSM-infected (middle panel) adult mice compared to controls given PBS (lower panel). One week after infection, the lungs were aseptically removed and fixed in formaldehyde. Sections were stained with hematoxylin and eosin and examined by light microscopy.

Fig. 9 are graphs illustrating the protection against *B. pertussis* in (a) adult and (b) infant mice or *B. paraptussis* in infant mice (d). Mice immunized with BPZE1, aPV or PBS (naïve) were challenged with BPSM (a and b) or *B. paraptussis* (d), and lung CFU counts were determined 3 h (white bars) or 7 days (black bars) later. Results are expressed as mean (\pm standard error) CFUs from 3-4 mice per group and are representative of two separate experiments. (b, *, *P* = 0.009; d, *, *P* = 0.007) (c) CFU counts 3 h after BPSM challenge in adult mice vaccinated with BPZE1 or aPV, compared to controls. Results obtained from 3 separate experiments are expressed as percentages of CFUs of each mouse relative of the average of CFUs in non-immunized group from the same experiment.

Fig. 10 are bar graphs illustrating the immune responses induced by BPZE1 or aPV immunization. (a) Anti-FHA IgG(H+L) titers and (b) IgG1/IgG2a ratios before (white bars) or 1 week after BPSM challenge (black bars) in BPZE1 or aPV immunized mice, compared to controls. (c) IFN- γ to IL-5 ratios produced by FHA-, PTX- or ConA-stimulated splenocytes from mice vaccinated 2 months before with BPZE1 (black bars) or aPV (white bars), compared to controls (gray bars). Antibodies and cytokines were measured in individual mice, and the results are expressed as mean values (\pm standard error) for 4 mice per group tested in triplicate.

Fig. 11 is the amino acid sequence of *pertussis* toxin (SEQ ID NO:1) (islet-activating protein S1). The first 34 amino acids are the signal sequence, while amino acids 35 to 269 are the mature chain.

Fig. 12 is the amino acid sequence of dermonecrotic toxin (SEQ ID NO:2).

Fig. 13 is the amino acid sequence of AmpG from *Bordetella pertussis* (SEQ ID NO:3).

Fig. 14 is the amino acid sequence of AmpG from *Escherichia coli* (SEQ ID NO:4).

Description of the Preferred Embodiments of the Present Invention

[0037] The invention is defined in the appended claims and any other aspects or embodiments set forth herein are for information only.

[0038] As used herein, the abbreviation "PTX" refers to *pertussis* toxin, which synthesizes and secretes an ADP-ribosylating toxin. PTX is composed of six polypeptides S1 to S5, the enzymatically active moiety is called S1. PTX has a 34 amino acid signal sequence, while the mature chain consists of amino acids 35 to 269. PTX is the major virulence

factor expressed by *B. pertussis*. The A moiety of these toxins exhibit ADP-ribosyltransferase activity and the B portion mediates binding of the toxin to host cell receptors and the translocation of A to its site of action (57).

[0039] As used herein the abbreviation "DNT" refers to *pertussis* dermonecrotic toxin, which is a heat labile toxin that induces localized lesions in mice and other laboratory animals when it is injected intradermally. It is lethal to mice when it is injected in low doses intravenously (58 to 61). DNT is considered to be a virulence factor for the production of turbinate atrophy in porcine atrophic rhinitis (62, 63).

[0040] As used herein the abbreviation "TCT" refers to tracheal cytotoxin, which is a virulence factor synthesized by *Bordetella*. TCT is a peptidoglycan fragment and has the ability to induce interleukin-1 production and nitric oxide synthase. It has the ability to cause stasis of cilia and has lethal effects on respiratory epithelial cells.

[0041] The term "mammal" encompasses any of various warm-blooded vertebrate animals of the class Mammalia, including humans, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young.

[0042] The term "attenuated" means a weakened, less virulent *Bordetella* strain that is capable of stimulating an immune response and creating protective immunity, but does not cause any illness.

[0043] The terminology "rapid protective immunity" means that immunity against *Bordetella* is conferred in a short time after administration of the mutated *Bordetella* strain of the present invention. By "short time" means vaccinated and challenged one week later. More specifically, there is a quick expansion of existing pathogen-specific peripheral lymphocytes, CD8⁺ cytotoxic effectors (CTLs) and CD4⁺ helper cells. The CD4⁺ helper cells induce B cell maturation and antibody production. Thus, lymphocytes with the memory pool are poised to rapidly proliferate at the time of subsequent infection.

[0044] The term "*Bordetella* strain" encompasses strains from *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*.

[0045] The expression "*Bordetella* infection" means an infection caused by at least one of the three following strains: *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*.

[0046] By "child" is meant a person or a mammal between 6 months and 12 years of age.

[0047] By the term "newborn" is meant, a person or a mammal that is between 1 day old and 24 weeks of age.

[0048] The term "treatment" as used herein is not restricted to curing a disease and removing its causes but particularly covered means to cure, alleviate, remove or lessen the symptoms associated with the disease of interest, or prevent or reduce the possibility of contracting any disorder or malfunction of the host body.

[0049] The terms "protection" and "prevention" are used herein interchangeably and mean that an infection by *Bordetella* is impeded.

[0050] "Prophylaxis vaccine" means that this vaccine prevents *Bordetella* infection upon future exposure.

[0051] By "preferentially towards the Th1 pathway" is meant that the Th1 pathway is favored over the Th2 pathway.

[0052] The term "immunogenic composition" means that the composition can induce an immune response and is therefore antigenic. By "immune response" means any reaction by the immune system. These reactions include the alteration in the activity of an organism immune system in response to an antigen and may involve, for example, antibody production, induction of cell-mediated immunity, complement activation or development of immunological tolerance.

[0053] More specifically, the present invention provides at least a triple mutated *Bordetella* strain that can be used as an immunogenic composition or a vaccine. It will be appreciated that the at least triple mutated *Bordetella* strain contains a mutated *ptx* gene, a deleted or mutated *dnt* gene and a heterologous *ampG* gene. The heterologous *ampG* gene product reduces in large quantities the amount of tracheal cytotoxin that is produced.

[0054] The present invention is not limited to only the triple mutants described above. Other additional mutations can be undertaken such as adenylate cyclase (AC) deficient mutants (64), lipopolysaccharide (LPS) deficient mutants (65), filamentous hemagglutinin (FHA) (66) and any of the bvg-regulated components (67).

[0055] The starting strain which is mutated can be any *Bordetella* strain including *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*. In one aspect the starting strain used to obtain the mutated *Bordetella* strain is *B. pertussis*.

[0056] The construction of the mutated *Bordetella* strain starts with replacing the *Bordetella ampG* gene in the strain with a heterologous *ampG* gene. Any heterologous *ampG* gene can be used in the present invention. These include all those gram-negative bacteria that release very small amounts of peptidoglycan fragments into the medium per generation. Examples of gram-negative bacteria include, but are not limited to *Escherichia coli*, *Salmonella*, *Enterobacteriaceae*, *Pseudomonas*, *Moraxella*, *Helicobacter*, *Stenotrophomonas*, *Legionella* and the like.

[0057] By replacing the *Bordetella ampG* gene with a heterologous *ampG* gene, the amount of tracheal cytotoxin (TCT) produced in the resulting strain expresses less than 1% residual TCT activity. In another embodiment, the amount of TCT toxin expressed by the resulting strain is between 0.6% to 1% residual TCT activity or 0.4% to 3% residual TCT activity or 0.3% to 5% residual TCT activity.

[0058] PTX is a major virulence factor responsible for the systemic effects of *B. pertussis* infections, as well as one of the major protective antigens. Due to its properties, the natural *ptx* gene is replaced by a mutated version so that the

enzymatically active moiety S1 codes for an enzymatically inactive toxin, but the immunogenic properties of the pertussis toxin are not affected. This can be accomplished by replacing the arginine (Arg) at position 9 of the sequence with a lysine (Lys). Furthermore, a glutamic acid (Glu) at position 129 is replaced with a glycine (Gly).

[0059] Other mutations can also be made such as those described in U.S. Patent 6,713,072 as well as any known or other mutations able to reduce the toxin activity to undetectable levels. Allelic exchange is first used to delete the *ptx* operon and then to insert the mutated version.

[0060] Finally, the *dnt* gene is then removed from the *Bordetella* strain by using allelic exchange. Besides the total removal, the enzymatic activity can also be inhibited by a point mutation. Since DNT is constituted by a receptor-binding domain in the N-terminal region and a catalytic domain in the C-terminal part, a point mutation in the *dnt* gene to replace Cys-1305 to Ala-1305 inhibits the enzyme activity of DNT (68). DNT has been identified as an important toxin in *Bordetella bronchiseptica* and displays lethal activity upon injection of minute quantities (26).

[0061] Besides allelic exchange to insert the mutated *ptx* gene and the inhibited or deleted *dnt* gene, the open reading frame of a gene can be interrupted by insertion of a genetic sequence or plasmid. This method is also contemplated in the present invention.

[0062] The triple mutated strain of the present invention is called a BPZE1 strain and has been deposited with the Collection Nationale de Cultures de Microorganismes (CNCM) in Paris, France on March 9, 2006 under the number CNCM I-3585. The mutations introduced into BPZE1 result in drastic attenuation, but allow the bacteria to colonize and persist. Thus, in another embodiment the present invention provides BPZE1, which can induce mucosal immunity and systemic immunity when administered. In another aspect the BPZE1 is administered intranasally.

[0063] The mutated *Bordetella* strains of the present invention can be used in immunogenic compositions. Such immunogenic compositions are useful to raise an immune response, either an antibody response and or preferably a T cell response in mammals. Advantageously, the T cell response is such that it protects a mammal against *Bordetella* infection or against its consequences.

[0064] The mutated *Bordetella* strains of the present invention can be used as live strains or chemically or heat-killed strains in the vaccines or immunogenic compositions. In one aspect, the live strains are used for nasal administration, while the chemically-or heat killed strains can be used for systemic or mucosal administration.

[0065] The immunogenic composition may further comprise a pharmaceutically suitable excipient or carrier and/or vehicle, when used for systemic or local administration. The pharmaceutically acceptable vehicles include, but are not limited to, phosphate buffered saline solutions, distilled water, emulsions such as an oil/water emulsions, various types of wetting agents sterile solutions and the like.

[0066] The immunogenic composition of the invention can also comprise adjuvants, *i.e.*, any substance or compound capable of promoting or increasing a T-cell mediated response, and particularly a CD4⁺-mediated or CD8⁺-mediated immune response against the active principle of the invention. Adjuvants such as muramyl peptides such as MDP, IL-12, aluminium phosphate, aluminium hydroxide, Alum and/or Montanide® can be used in the immunogenic compositions of the present invention.

[0067] It would be appreciated by the one skilled in the art that adjuvants and emulsions in the immunogenic compositions are used when chemically or heat treated mutated *Bordetella* strains are used in the vaccines or immunogenic compositions.

[0068] The immunogenic compositions of the invention further comprise at least one molecule having a prophylactic effect against a *Bordetella* infection or the detrimental effects of *Bordetella* infection, such as a nucleic acid, a protein, a polypeptide, a vector or a drug.

[0069] The immunogenic composition of the invention is used to elicit a T-cell immune response in a host in which the composition is administered. All immunogenic compositions described above can be injected in a host via different routes: subcutaneous (s.c.), intradermal (i.d.), intramuscular (i.m.) or intravenous (i.v.) injection, oral administration and intranasal administration or inhalation.

[0070] When formulated for subcutaneous injection, the immunogenic composition or vaccine of the invention preferably comprises between 10 and 100 µg of the *Bordetella* strain per injection dose, more preferably from 20 to 60 µg/dose, especially around 50 µg/dose, in a sole injection.

[0071] When formulated for intranasal administration, the *Bordetella* strain is administered at a dose of approximately 1×10^3 to 1×10^6 bacteria, depending on the weight and age of the mammal receiving it. In another aspect a dose of 1×10^4 to 5×10^6 can be used.

[0072] The mutated *Bordetella* strains of the present invention can be used as an attenuated vaccine to protect against future *Bordetella* infection. In this regard, an advantage of the present invention is that a single dose can be administered to mammals and the protection can last at least for a duration of longer than two months, particularly longer than six months. The vaccine of the present invention can be administered to newborns and protects against infection of whooping cough. This is especially crucial since the fatality rate from *Bordetella pertussis* infections is about 1.3% for infants younger than 1 month.

[0073] Moreover, the vaccines of the present invention can be used in adult mammals when there is a epidemic or in

older adults over the age of 60, since their risk of complications maybe higher than that of older children or healthy adults.

[0074] The vaccines can be formulated with the physiological excipients set forth above in the same manner as in the immunogenic compositions. For instance, the pharmaceutically acceptable vehicles include, but are not limited to, phosphate buffered saline solutions, distilled water, emulsions such as an oil/water emulsions, various types of wetting agents sterile solutions and the like. Adjuvants such as muramyl peptides such as MDP, IL-12, aluminium phosphate, aluminium hydroxide, Alum and/or Montanide® can be used in the vaccines.

[0075] The vaccines of the present invention are able to induce high titers of serum IgG against FHA. The analysis of the antigen-specific cytokine patterns revealed that administration with the mutated attenuated *Bordetella* strains of the present invention favored a strong TH1 response.

[0076] The vaccines of the present invention provide high level of protection against a *Bordetella* infection *i.e.*, a level of protection higher than 90%, particularly higher than 95%, more particularly higher than 99% (calculated 7 days after infection as detailed on example 9). The level of protection of the vaccine comprising the BPZE1 strain reaches more than 99.999% compared to non-vaccinated (naïve) mice, at least two months after vaccination.

[0077] The vaccines can be administered subcutaneous (s.c.), intradermal (i.d.), intramuscular (i.m.) or intravenous (i.v.) injection, oral administration and intranasal administration or inhalation. The administration of the vaccine is usually in a single dose. Alternatively, the administration of the vaccine of the invention is made a first time (initial vaccination), followed by at least one recall (subsequent administration), with the same strain, composition or vaccine, or with acellular vaccines, or a combination of both.

[0078] In one aspect, intranasal administration or inhalation of the vaccines is accomplished, which type of administration is low in costs and enables the colonization by the attenuated strains of the invention of the respiratory tract: the upper respiratory tract (nose and nasal passages, paranasal sinuses, and throat or pharynx) and/or the respiratory airways (voice box or larynx, trachea, bronchi, and bronchioles) and/or the lungs (respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli)

[0079] Intranasal administration is accomplished with an immunogenic composition or a vaccine under the form of liquid solution, suspension, emulsion, liposome, a cream, a gel or similar such multiphasic composition. Solutions and suspensions are administered as drops. Solutions can also be administered as a fine mist from a nasal spray bottle or from a nasal inhaler. Gels are dispensed in small syringes containing the required dosage for one application.

[0080] Inhalation is accomplished with an immunogenic composition or a vaccine under the form of solutions, suspensions, and powders; these formulations are administered via an aerosol or a dry powder inhaler. Compounded powders are administered with insufflators or puffers.

[0081] Use of the mutated *Bordetella* strains comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene and a heterologous *ampG* gene for the preparation of a multivalent vaccine to treat respiratory diseases is yet another aspect of the present invention. In this regard, the attenuated mutated *Bordetella* strain described above, can be used as an heterologous expression platform to carry heterologous antigens to the respiratory mucosa. Thus, such respiratory pathogens such as *Neisseria*, *Pneumophila*, *Yersinia*, *Pseudomonas*, *Mycobacteria*, *Influenza* and the like can prevent infection using the BPZE1 as a carrier.

[0082] Use of the live attenuated mutated *Bordetella* strains described herein for the manufacture of a vaccine for the treatment or prevention of *Bordetella* infection is also encompassed by the present invention. In this regard, the vaccine can be used for the simultaneous treatment or prevention of an infection by *B. pertussis* and *B. parapertussis*.

[0083] Use of the vaccine to provide rapid protective immunity in case of a *pertussis* epidemic is also encompassed by the present invention.

[0084] Use of the vaccine to provide a rapid protective immunity, increasing over the at least next two months following vaccination is also encompassed by the present invention.

[0085] The vaccine or immunogenic composition is also provided in a kit. The kit comprises the vaccine or immunogenic composition and an information leaflet providing instructions for immunization.

[0086] The present invention also relates to a method for inducing T-cell mediated immune response and particularly a CD4⁺-mediated immune response or a CD8⁺-mediated immune response, comprising administering the live attenuated *Bordetella* strains of the invention in a non-human mammal or a human mammal.

[0087] A method of protecting a mammal against disease caused by infection by *Bordetella* comprising administering to said mammal in need of such treatment a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene is another embodiment of the present invention. This method encompasses treating or preventing infections against *Bordetella pertussis* and/or *Bordetella parapertussis*. In one aspect the BPZE1 strain is used in this method.

[0088] Also a method of providing a rapid protective immunity against a *Bordetella* infection comprising administering to said mammal in need of such treatment a mutated *Bordetella* strain comprising at least a mutated *ptx* gene, a deleted or mutated *dnt* gene, and a heterologous *ampG* gene is encompassed by the present invention. In one aspect the BPZE1 strain is used in this method.

[0089] Moreover, the mutated live attenuated *Bordetella* strains of the present invention induce mucosal immunity, as

well as systemic immunity. Thus, in another aspect the invention also relates to a method of inducing mucosal and systemic immunity by administering to a mammal in need of such treatment the mutated live attenuated *Bordetella* strains of the present invention. In one aspect the BPZE1 strain is used in this method.

[0090] Besides its role in the prevention and/or treatment of *Bordetella* infection, the mutated strain of the invention may be used as vector, to bear at least one further heterologous nucleic acid sequence encoding a RNA (such as antisense RNA) or a protein of interest. This means that the mutated strain bears at least one further heterologous nucleic acid sequence in addition to the heterologous *ampG* gene. In one aspect, the protein encoded by this at least one further heterologous nucleic acid sequence is a protein for which the expression is desired in the respiratory tract. In another aspect, the protein of interest is an antigen, such as a viral, a bacterial or a tumoral antigen, against which an immune response is desired. Therefore, the mutated *Bordetella* strain bearing at least one further heterologous nucleic acid sequence may also be used as a vaccine. The definitions given above for administration of the vaccine or immunogenic composition also apply to a vaccine comprising mutated *Bordetella* strain bearing at least one further heterologous nucleic acid sequence. Examples of heterologous proteins are antigens of pathogens causing infections of or diseases associated with the respiratory track: poliomyelitis, influenza (*influenzavirus* from *Orthomyxoviridae* family) or antigens from pneumococcus (such as *Streptococcus pneumoniae*).

EXAMPLES

MATERIALS AND METHODS

Example 1 - *Bordetella* strains and growth conditions

[0091] The *B. pertussis* strains used in this study were all derived from *B. pertussis* BPSM [13], and *B. parapertussis* is a streptomycin-resistant derivative of strain 12822 (kindly provided by Dr. N. Guiso, Institut Pasteur Paris, France). All *Bordetella* strains were grown on Bordet-Gengou (BG) agar (Difco, Detroit, Mich.) supplemented with 1% glycerol, 20% defibrinated sheep blood, and 100 µg/ml streptomycin. For cell adherence assays, exponentially growing *B. pertussis* was inoculated at an optical density of 0.15 at 600 nm in 2.5 ml modified Stainer-Scholte medium [14] containing 1 g/l heptakis(2,6-di-o-methyl) β-cyclodextrin (Sigma) and supplemented with 65 µCi/ml L-[³⁵S]methionine plus L-[³⁵S]cysteine (NEN, Boston, Mass.) and grown for 24 h at 37°C. The bacteria were then harvested by centrifugation, washed three times in phosphate-buffered saline (PBS) and resuspended in RPMI 1640 (Gibco, Grand Island, N. Y.) at the desired density.

Example 2 - Construction of *B. pertussis* BPZE1.

[0092] To construct *B. pertussis* BPZE1, the *B. pertussis ampG* gene was replaced by *Escherichia coli ampG* using allelic exchange. A PCR fragment named *met* and located at position 49,149 to 49,990 of the *B. pertussis* genome (http://www.sanger.ac.uk/Projects/B_pertussis/), upstream of the *B. pertussis ampG* gene, was amplified using oligonucleotides A : 5'-TATAAATCGATATTCCTGCTGGTTTCGTTCTC-3' (SEQ ID No:5) and B : 5'-TATAGCTAGCAAGTTGGGAAACGACACCAC-3' (SEQ ID No:6), and *B. pertussis* BPSM [13] genomic DNA as a template. This 634-bp fragment was inserted into Topo PCR II (Invitrogen Life Technology, Groningen, The Netherlands) and then excised as a *Clal*-*NheI* fragment and inserted into *Clal*- and *NheI*-digested pBP23 [50], a suicide vector containing the *E. coli ampG* gene with flanking *B. pertussis* DNA of 618 bp (from position 50,474 to 51,092 of the *B. pertussis* genome) and 379 bp (from position 52,581 to 52,960 of the *B. pertussis* genome) at the 5' and 3' end of *E. coli ampG*, respectively. The resulting plasmid was transferred into *E. coli* SM10 [51], which was then conjugated with BPSM, and two successive homologous recombination events were selected as described [52]. Ten individual colonies were screened by PCR as follows. The colonies were suspended in 100 µl H₂O, heated for 20 min. at 95°C, and centrifuged for 5 min at 15,000 x g. One µl of supernatants was then used as template for PCR using oligonucleotides A and C : 5'-TAAGAAGCAAAATAAGCCAGGCATT-3' (SEQ ID No:7) to verify the presence of *E. coli ampG* and using oligonucleotides D : 5'-TATACCATGGCGCCGCTGCTGGTGCTGGGC-3' (SEQ ID No:8) and E : 5'-TATATCTAGACGCTGGCCGTAAACCTTAGCA-3' (SEQ ID No:9) to verify the absence of *B. pertussis ampG*. One of the strains containing *E. coli ampG* and lacking *B. pertussis ampG* was then selected, and the entire *ampG* locus was sequenced. This strain was then used for further engineering. [0093] The *ptx* genes were deleted from the chromosome of this strain as described [21] and then replaced by mutated *ptx* coding inactive PTX. The *EcoRI* fragment containing the mutated *ptx* locus from pPT-RE [16] was inserted into the *EcoRI* site of pJQ200mp18rpsI [53]. The resulting plasmid was integrated into the *B. pertussis* chromosome at the *ptx* locus by homologous recombination after conjugation via *E. coli* SM10. The *ptx* locus in the chromosome of the resulting *B. pertussis* strain was sequenced to confirm the presence of the desired mutations. Toxin production was analyzed by immunoblotting using a mix of monoclonal antibodies IB7 [54] specific for subunit S1, and 11E6 [55] specific for subunits S2 and S3 of PTX.

[0094] Finally, the *dnt* gene was deleted from the resulting *B. pertussis* strain as the *dnt* flanking regions were amplified by PCR using BPSM genomic DNA as a template and oligonucleotides F: 5'-TATAGAATTCGCTCGGTTTCGCTGGT-CAAG G-3' (SEQ ID No:10) and G: 5'-TATATCTAGAGCAATGCCGATTCATCTTTA-3' (SEQ ID No:11) for the *dnt* upstream region, and H: 5'-TATATCTAGAGCGGCCTT TATTGCTTTTCC-3' (SEQ ID No:12) and I: 5'-TATAAAGCT-TCTCATGCACGCCG GCTTCTC-3' (SEQ ID No:13) for the *dnt* downstream region, as primers. The resulting 799-bp and 712-bp DNA fragments were digested with *EcoRI/XbaI* and *XbaI/HindIII*, respectively, and linked together using the Fast Link kit (Epicentre Biotechnologies, Madison, WI). The ligated fragment was amplified by PCR using oligonucleotides F and I, and the 1505-bp PCR fragment was then inserted into pCR2.1-Topo (Invitrogen), re-isolated from the resulting plasmid as an *EcoRI* fragment and inserted into the unique *EcoRI* site of pJQmp200rpsL18. The resulting plasmid was introduced into *B. pertussis* by conjugation via *E. coli* SM10. Successful deletion of the *dnt* gene by allelic exchange was verified by Southern blot analysis on PvuII-digested *B. pertussis* genomic DNA using the PCR fragment corresponding to the *dnt* upstream region as a probe. The probe was labeled with digoxigenin (DIG) using the DIG Easy Hyb labeling kit (Roche, Meylan, France). The sizes of the hybridizing bands were determined from the migration distance of the Dig-labeled DNA molecular marker III (Roche). The *dnt* locus of this final strain, named BPZE1 was sequenced.

Example 3 - Analysis of TCT production.

[0095] For sensitive quantitation of TCT production, culture supernatants of *B. pertussis* grown to logarithmic phase were collected, subjected to solid phase extraction [15] and derivatized with phenylisothiocyanate (PITC, Pierce). The resulting phenylthiocarbamyl (PTC) derivatives were separated by reversed-phase HPLC using a C8 column (Perkin Elmer) and detected at 254 nm. The amount of *B. pertussis* PTC-TCT in each sample was determined by comparing the peak area and elution time with an identically processed TCT standard.

Example 4 - Cell-adherence assay.

[0096] To analyze adherence properties of the *B. pertussis* strains, their attachment rates to the human pulmonary epithelial cell line A549 (ATCC n°CCL-185) and the murine macrophage cell line J774 (ATCC n°TIB-67) were measured as previously described [16].

Example 5 - Transmission electron microscopy.

[0097] The single droplet-negative staining procedure was used as described previously [17] with the following modifications. 20 μ l of a suspension at approximately 10^9 bacteria/ml were absorbed for 2 min. onto form varnish carbon-coated nickel grids (400 mesh; Electron Microscopy Sciences EMS, Washington, PA). After 30 seconds air-drying the grids were stained for 2 minutes with 20 μ l of 2% phosphotungstic acid (pH7; EMS) and examined after air-drying under a transmission electron microscope (Hitachi 7500, Japan) at 60 kvolts and high resolution.

Example 6 - Intranasal infection and vaccination.

[0098] 3-week and 8-week old female Balb/C were kept under specific pathogen-free conditions, and all experiments were carried out under the guidelines of the Institut Pasteur de Lille animal study board. Mice were intranasally infected with approximately 4×10^6 bacteria in 20 μ l PBS, and kinetics of CFU in the lungs were measured as previously described [18]. For vaccination with aPV (Tetravac; Aventis-Pasteur, France), mice were immunized intraperitoneally (i.p.) with 20% of the human dose and boosted one month later using the same dose.

Example 7 - Antibody determination.

[0099] Sera were collected, and antibody titers were estimated by enzyme-linked immunosorbent assays (ELISA) as previously described [18].

Example 8 - Cytokine assays.

[0100] Spleen cells from individual mice were tested at different time points after immunization for *in vitro* cytokine production in response to heat-killed *B. pertussis* BPSM (10^6 cells/ml), 5.0 μ g/ml PTX (purified from *B. pertussis* BPGR4 [19] as previously described [20] and heat-inactivated at 80°C for 20 min), 5.0 μ g filamentous hemagglutinin (FHA, purified from *B. pertussis* BPRA [21] as previously described [22]), 5 μ g/ml concanavalin A (Sigma Chemical Co., St. Louis, Mo.) or medium alone as control. Supernatants were removed from triplicate cultures after 72 h incubation at 37°C and 5% CO₂, and IFN- γ and IL-5 concentrations were determined by immunoassays (BD OptEIA set, Pharmingen).

Example 9 - Intranasal infection and vaccination: challenge at 1, 2, 3 and 4 weeks.

[0101] An infant (3 weeks-old) mouse model [29] was used to compare the efficiency of vaccination with BPZE1 with the one of vaccination with acellular *pertussis* vaccine (aPv). Female Balb/C mice were intranasally infected with approximately 1×10^6 BPZE1 strain in 20 μ l PBS. For vaccination with aPv (Tetrevac; Aventis-Pasteur, France), mice were immunized intraperitoneally with 20% of the human dose. One, two, three or four weeks after vaccination with BPZE1 or aPv, mice were intranasally challenged with virulent *B. pertussis* BPSM/bctA-lacZ strain [53]. This strain is a BPSM-derivative gentamycin-resistant which allows the discrimination with BPZE1 (gentamycin-sensitive) on Bordet-Gengou agar plates containing 10 μ g/ml of gentamycin and 100 μ g/ml of streptomycin (BGgs). Control group corresponds to naive mice challenged with BPSM/bctA-lacZ. One week after challenge infection, lungs were aseptically removed, homogenized and plates on BGgs for CFU determination as previously described [18].

[0102] Mice were vaccinated with BPZE1 or aPv and challenged with virulent *B. pertussis* one, two, three or four weeks after vaccination. Lung CFUs counts were determined 3 hours or 7 days later. Results are expressed as mean (\pm standard error) CFUs from three to five mice per group. Levels of protection are calculated for each challenge infection as mean percentages of CFUs of each group relative of the average of CFUs in non-immunized group, 7 days after challenge infection (Tables 2 to 5).

Example 10 - Statistical analysis.

[0103] The results were analyzed using the unpaired Student's t test and the Kruskal-Wallis test followed by the Dunn's post-test (GraphPad Prism program) when appropriate. Differences were considered significant at $P \leq 0.05$.

RESULTS**Construction of *B. pertussis* BPZE1**

[0104] Three virulence factors were genetically targeted: tracheal cytotoxin (TCT), pertussis toxin (PTX) and dermonecrotic toxin (DNT).

[0105] TCT is responsible for the destruction of ciliated cells in the trachea of infected hosts [24, 25] and may thus be involved in the cough syndrome. TCT is a breakdown product of peptidoglycan in the cell wall of Gram-negative bacteria, which generally internalize it into the cytosol by the AmpG transporter protein to be re-utilized during cell wall biosynthesis. *B. pertussis* AmpG is inefficient in the internalization of peptidoglycan breakdown products. We therefore replaced the *B. pertussis* *ampG* gene by *E. coli* *ampG*. The resulting strain expressed less than 1 % residual TCT activity (Fig. 1).

[0106] PTX is a major virulence factor responsible for the systemic effects of *B. pertussis* infections and is composed of an enzymatically active moiety, called S1, and a moiety responsible for binding to target cell receptors (for review, see 26). However, it is also one of the major protective antigens, which has prompted us to replace the natural *ptx* genes by a mutated version coding for an enzymatically inactive toxin. This was achieved by replacing Arg-9 by Lys and Glu-129 by Gly in S1, two key residues involved in substrate binding and catalysis, respectively. Allelic exchange was used to first delete the *ptx* operon, and then to insert the mutated version. The presence of the relevant toxin analogues in the *B. pertussis* culture supernatants was evaluated by immunoblot analysis (Fig. 2).

[0107] Finally, allelic exchange was used to remove the *dnt* gene (Fig. 3). Although the role of DNT in the virulence of *B. pertussis* is not certain, it has been identified as an important toxin in the closely related species *Bordetella bronchiseptica* and displays lethal activity upon injection of minute quantities (for review, see 26).

In vitro characterization of *B. pertussis* BPZE1

[0108] Since some of the genetic alterations in BPZE1 may potentially affect the bacterial cell wall synthesis, the size and shape, as well as the *in vitro* growth rate of BPZE1 was compared with those of the parental strain BPSM. The growth rate of BPZE1 did not differ from that of BPSM (Fig. 4), and no difference in bacterial shape or size was detected between BPZE1 and BPSM, as evidenced by electron microscopy analysis (Fig. 5). However, the cell wall of BPZE1 appeared to be consistently somewhat thinner than that of BPSM.

[0109] To determine whether the absence or alterations of any of the targeted toxins in BPZE1 affects adherence properties of *B. pertussis*, the attachment rates of BPZE1 was compared with those of BPSM, using the human pulmonary epithelial cell line A549 and the murine macrophage cell line J774, as two cellular models often used to study the adherence of *B. pertussis*. No significant difference in the adherence capacities to either cell line was observed between the two strains (Fig. 6).

Attenuation of *B. pertussis* BPZE1

[0110] To determine whether the mutations introduced into *B. pertussis* BPZE1 have resulted in attenuation, yet allow the organism to colonize the respiratory tract, Balb/C mice were intranasally infected with BPZE1 or BPSM, and colonization was followed over time. BPZE1 was able to colonize and persist in the lungs of mice as long as BPSM (Fig. 7). However, the peak of multiplication seen 7 days after infection with BPSM was consistently lacking in mice infected with BPZE1. Studies done with strains mutated in individual toxin genes indicated that this is due to the mutations in the *ptx* locus (data not shown). When the lungs were examined for histopathological changes and inflammatory infiltration, infection with BPSM was found to induce strong peri-bronchiovascular infiltrates and inflammatory cell recruitment 7 days after infection, associated with a strong hypertrophy of the bronchiolar epithelial cells (Fig. 8). In contrast, no such changes were seen in BPZE1-infected animals, and the histology of the BPZE1-infected mice was similar to that of the control mice that had received PBS instead of the bacteria. The BPSM-infection induced inflammation lasted for at least two months (data not shown). These results indicate that the mutations introduced into BPZE1 have resulted in drastic attenuation, but allow the bacteria to colonize and persist in the lungs.

Protection against *B. pertussis* challenge after intranasal vaccination of adult mice with BPZE1

[0111] To evaluate the protection offered by BPZE1, the effect of a single intranasal administration of this strain to 8-weeks old Balb/C mice on the subsequent colonization by the wild type challenge strain BPSM was compared with that of two i. p. immunizations with 1/5 of a human dose of aPV. This aPV immunization protocol has been described as the best to correlate with pertussis vaccine efficacy in human clinical trials [27, 28]. As shown by the total clearance of bacterial colony counts in the lungs seven days after challenge infection, a single intranasal administration of BPZE1 and two i.p. immunizations with aPV provided similar levels of protection (Fig. 9a). High bacterial loads were found in the control mice that had received two injections of PBS instead of the vaccine.

Protection against *B. pertussis* challenge after intranasal vaccination of infant mice with BPZE1

[0112] Since the principal targets of novel *pertussis* vaccines are young infants, that are not protected with the currently available vaccines, an infant (3 weeks-old) mouse model [29] was developed and used to compare the efficiency of vaccination with BPZE1 with that of vaccination with aPV. A single nasal administration of BPZE1 fully protected infant mice against challenge infection (Fig. 9b), as complete bacterial clearance was observed in the lungs one week after challenge. In contrast, substantial numbers of bacteria remained in the aPV-vaccinated animals one week after challenge infection. The difference in bacterial load between the BPZE1-vaccinated and the aPV-vaccinated mice was statistically significant, indicating that in the infant mouse model a single intranasal administration with BPZE1 provides better protection than two systemic administrations of aPV.

[0113] In addition, a strong reduction in the bacterial load of the challenge strain 3 hours after administration when the mice had been immunized with BPZE1 was consistently observed compared to the aPV-immunized animals (Fig. 9c), indicating that vaccination with BPZE1 reduces the susceptibility to infection by the challenge strain. This effect was seen in both 8-weeks old and in infant mice. In contrast, aPV had no effect on the bacterial counts 3 hours after infection, when compared to the control mice.

Protection against *B. paraptussis* challenge after intranasal vaccination with BPZE1

[0114] There is increasing concern about *B. paraptussis* infection in children, especially in immunized populations [30, 31]. *B. paraptussis* causes a milder *pertussis*-like syndrome, the frequency of which is probably largely underestimated. Furthermore, the incidence of *B. paraptussis* infections has been increasing over the last decades, possibly due to the fact that *pertussis* vaccines are known to have very low or no protective efficacy against *B. paraptussis* [32, 33]. In contrast, infection by *B. pertussis* has recently been reported to protect against *B. paraptussis* infection [34]. BPZE1 was also assessed for protection against *B. paraptussis* using the infant mouse model. Whereas two administrations of aPV did not provide any protection against *B. paraptussis*, as previously reported, a single intranasal administration of BPZE1 provided strong protection, as measured by the low numbers of *B. paraptussis* counts in the lungs of the vaccinated mice 1 week after challenge (Fig. 9d).

Immune responses induced by BPZE1 vaccination

[0115] Although the mechanisms of protective immunity against *B. pertussis* infection are not yet completely understood, clear evidence of a role for both B cells and IFN- γ has been demonstrated in mice [28]. Vaccination with either one nasal dose of BPZE1 or two i. p. administrations of aPV induced high titers of serum IgG against FHA, a major

surface antigen of *B. pertussis* [35], also present in aPV (Fig. 10a). Following *B. pertussis* challenge, positive anamnestic responses were measured in BPZE1- and in aPV-vaccinated animals, as indicated by an increase in anti-FHA IgG titers, compared to primary responses before *B. pertussis* infection. Examination of the anti-FHA IgG1/IgG2a ratios showed that these ratios were higher after aPV administration, characteristic of a Th2 type response, than after BPZE1 vaccination (Fig. 10b). Although the anti-FHA-IgG1/IgG2a decreased after challenge in the aPV vaccinated mice, it remained still substantially higher than in the BPZE1-vaccinated animals after *B. pertussis* challenge.

[0116] Analysis of *B. pertussis* antigen-specific cytokine patterns induced by BPZE1 or aPV vaccination confirmed that BPZE1 administration favors a stronger Th1 type response than aPV vaccination. This was revealed by the fact that the ratios of IFN- γ over IL-5 produced by splenocytes stimulated with FHA or PT, or with the polyclonal activator ConA were significantly higher in BPZE1 vaccinated mice than in aPV vaccinated mice (Fig. 10c).

Protective immunity of BPZE1 over time (from 1 week to 4 weeks)

[0117] As shown in Tables 1 to 5 below, whereas administration of aPv provided limited protection (reduction of 75% of bacterial load compared to non-vaccinated mice at 1 week) against *B. pertussis*, a single intranasal administration of BPZE1 already provided high level of protection (reduction of 97.64 % of bacterial load) against a *B. pertussis* challenge infection performed one week after vaccination. If challenge infection occurred two weeks after vaccination, the level of protection induced by BPZE1 reached more than 99.999 % compared to non-vaccinated mice and is significantly superior to the protection induced by aPv vaccine (approximately 92 % compared to non-vaccinated mice). Therefore, vaccine efficacy of BPZE1 against *B. pertussis* challenge is already significant one week after vaccination and is increasing over the at least next two months.

Table 1 : Kinetics of vaccines efficacy against *B. pertussis* challenge in infant mice.

Time between vaccination and challenge	Time between lungs recovery and challenge	Log10 cfu / lungs of mice		
		Naive	aPv-vaccinated	BPZE1-vaccinated
1 week	3 hours	5.71 \pm 0.03	5.8 \pm 0.07	5.74 \pm 0.01
	7 days	6.71 \pm 0.06	5.97 \pm 0.20	4.86 \pm 0.35
2 weeks	3 hours	5.77 \pm 0.10	5.60 \pm 0.02	5.49 \pm 0.05
	7 days	6.49 \pm 0.08	5.31 \pm 0.16	3.22 \pm 0.33
3 weeks	3 hours	6.03 \pm 0.11	5.88 \pm 0.04	5.33 \pm 0.08
	7 days	6.58 \pm 0.09	5.62 \pm 0.11	3.14 \pm 0.38
4 weeks	3 hours	6.31 \pm 0.01	6.15 \pm 0.02	5.83 \pm 0.05
	7 days	6.36 \pm 0.04	5.21 \pm 0.11	1.83 \pm 0.46

Table 2: Level of protection of aPv-vaccinated and BPZE1-vaccinated mice as compared to non-vaccinated mice at week 1.

Non vaccinated mice	Number of bacteria in lungs	Mean number of bacteria		
Non-vaccinated 1	4.7x10 ⁶	5.36.10 ⁶		
Non-vaccinated 2	3.8x10 ⁶			
Non-vaccinated 3	8.2x10 ⁶			
Non-vaccinated 4	4.1x10 ⁶			
Non-vaccinated 5	6x10 ⁶			
	Number of bacteria in lungs	Percentage of remaining bacteria ⁽¹⁾	Mean percentage of remaining bacteria	Level of protection
aPv-vaccinated mice				
aPv1	1.95x10 ⁶	36.38	25 %	75 %
aPv2	2.9x10 ⁶	54.1		
aPv3	2.9x10 ⁵	5.41		
aPv4	3.6x10 ⁵	6.72		
aPv5	1.2x10 ⁶	22.39		
BPZE1-vaccinated mice				
BPZE1-1	3.2x10 ⁵	5.97	2.36 %	97.64 %
BPZE1-2	2x10 ⁴	0.004		
BPZE1-3	6x10 ⁴	1.12		
(1) Percentage of remaining bacteria = number of bacteria for each particular mouse / mean number of bacteria of all non-vaccinated mice				

Table 3: Level of protection of aPv-vaccinated and BPZE1-vaccinated mice as compared to non-vaccinated mice at week 2.

Non vaccinated mice	Number of bacteria in lungs	Mean number of bacteria		
Non-vaccinated 1	5×10^6	3.34×10^6		
Non-vaccinated 2	3.6×10^6			
Non-vaccinated 3	1.7×10^6			
Non-vaccinated 4	2.4×10^6			
Non-vaccinated 5	4×10^6			

(continued)

Non vaccinated mice	Number of bacteria in lungs	Mean number of bacteria		
	Number of bacteria in lungs	Percentage of remaining bacteria ⁽¹⁾	Mean percentage of remaining bacteria	Level of protection
aPv-vaccinated mice				
aPv1	9.5 x10 ⁴	2.84	8.11 %	91.89 %
aPv2	2.9x10 ⁵	8.68		
aPv3	1x10 ⁵	2.99		
aPv4	6.8x10 ⁵	20.36		
aPv5	1.9x10 ⁵	5.69		
BPZE1-vaccinated mice				
BPZE1-1	9.5 x10 ³	2.8x10 ⁻³	1.03 x10 ⁻³ %	99.999 %
BPZE1-2	450	1.35 x10 ⁻⁴		
BPZE1-3	3500	1.05x10 ⁻³		
BPZE1-4	500	1.5x10 ⁻⁴		
(1) Percentage of remaining bacteria = number of bacteria for each particular mouse / mean number of bacteria of all non-vaccinated mice				

Table 4: Level of protection of aPv-vaccinated and BPZE1-vaccinated mice as compared to non-vaccinated mice at week 3.

Non vaccinated mice	Number of bacteria in lungs	Mean number of bacteria		
Non-vaccinated 1	1.8x10 ⁶	4.04x10 ⁶		
Non-vaccinated 2	5.75x10 ⁶			
Non-vaccinated 3	4.7x10 ⁶			
Non-vaccinated 4	3.2x10 ⁶			
Non-vaccinated 5	4.75 x10 ⁶			
	Number of bacteria in lungs	Percentage of remaining bacteria ⁽¹⁾	Mean percentage of remaining bacteria	Level of protection
aPv-vaccinated mice				
aPv1	1.99x10 ⁵	4.94	11.26 %	88.74 %
aPv2	6x10 ⁵	14.85		
aPv3	6x10 ⁵	14.85		
aPv4	4.2x10 ⁵	10.40		

(continued)

BPZE1-vaccinated mice				
BPZE1-1	3640	9.01 x10 ⁻⁴	8.65x10 ⁻⁴ %	99.999 %
BPZE1-2	9720	2.4x10 ⁻³		
BPZE1-3	300	7.43 x10 ⁻⁵		
BPZE1-4	340	8.42x10 ⁻⁵		
(1) Percentage of remaining bacteria = number of bacteria for each particular mouse / mean number of bacteria of all non-vaccinated mice				

Table 5: Level of protection of aPv-vaccinated and BPZE1-vaccinated mice as compared to non-vaccinated mice at week 4.

Non vaccinated mice	Number of bacteria in lungs	Mean number of bacteria		
Non-vaccinated 1	2.1x10 ⁶	2.36x10 ⁶		
Non-vaccinated 2	2.2x10 ⁶			
Non-vaccinated 3	3.1x10 ⁶			
Non-vaccinated 4	2.6x10 ⁶			
Non-vaccinated 5	1.8 x10 ⁶			
	Number of bacteria in lungs	Percentage of remaining bacteria ⁽¹⁾	Mean percentage of remaining bacteria	Level of protection
aPv-vaccinated mice				
aPv1	2.52 x10 ⁵	10.68	7.76 %	92.24 %
aPv2	3.28 x10 ⁵	13.90		
aPv3	1.04x10 ⁵	4.41		
aPv4	8.4x10 ⁵	3.56		
aPv5	1.48x10 ⁵	6.27		
BPZE1-vaccinated mice				
BPZE1-1	190	8.05 x10 ⁻⁵	7.13 x10 ⁻⁵ %	99.999 %
BPZE1-2	0	0		
BPZE1-3	110	4.66 x10 ⁻⁵		
BPZE1-4	320	1.36 x10 ⁻⁴		
BPZE1-5	220	9.32x10 ⁻⁵		
(1) Percentage of remaining bacteria = number of bacteria for each particular mouse / mean number of bacteria of all non-vaccinated mice				

DISCUSSION

[0118] *Pertussis* is the first infectious disease whose incidence is increasing in countries with high vaccine coverage. This paradoxical situation is most likely linked to the epidemiological changes observed since the massive introduction of highly efficacious vaccines. In contrast to the pre-vaccination era, cases of adolescent and adult *pertussis* are now increasingly more frequent. Although generally not life-threatening in that age group, *B. pertussis*-infected adults are an important reservoir for infection of the very young children, too young to be protected by vaccination. Early vaccination, possibly at birth, would therefore be highly desirable, but is hampered by the immaturity of the immune system of neonates and infants. However, the fact that natural *B. pertussis* infection, even very early in life, is able to induce a strong Th1 response in infants [12] prompted us to develop a live attenuated *B. pertussis* vaccine strain to be given by the nasal route as an alternative over the currently available vaccines.

[0119] Based on experimental infections of primates, Huang *et al.* had already in 1962 come to the conclusion that ultimate protection against whooping cough probably best follows a live *B. pertussis* inoculation [36]. In veterinary medicine, attenuated *Bordetella* strains have been used to vaccinate against bordetellosis in dogs and piglets. A live attenuated *Bordetella bronchiseptica* strain has been shown to provide strong protection against kennel cough in dogs [37] after nasal administration. This protection was seen as early as 48 h after vaccination. Intranasal vaccination with live attenuated *B. bronchiseptica* has also been shown to protect against atrophic rhinitis in two-days old piglets [38], indicating that in a live attenuated form *Bordetella* vaccines can be highly active in new-born animals.

[0120] Previous attempts to genetically attenuate *B. pertussis* as a live vaccine candidate have met with rather limited success. Based on a strategy used for the successful attenuation of *Salmonella* vaccine strains [39], Roberts *et al.* have deleted the *aroA* gene of *B. pertussis* [40]. The *aroA* mutant was indeed highly attenuated, but had also lost its capacity to colonize the respiratory tract of the intranasally vaccinated animals and induced protective immunity only after repeated administrations of high doses. We took advantage of the knowledge on the molecular mechanisms of *B. pertussis* virulence and developed the highly attenuated strain BPZE1. This strain contains genetic alterations leading to the absence or inactivation of three major toxins, PTX, TCT and DNT. In contrast to the *aroA* mutant, this strain was able to colonize the mouse respiratory tract and to provide full protection after a single intranasal administration. The protection in adult mice was indistinguishable from that induced by two administrations of 1/5 of a human dose of aPV. An important difference, however, was seen in infant mice, where a single administration of BPZE1 fully protected, whereas aPV only offered partial protection. In the context of the difficulties to induce protection in infants with the currently available vaccines early in life, these results provide hope for the development of novel vaccination strategies that may be used in the very young children, possibly at birth. In addition, BPZE1 protected against *B. parapertussis*, whereas aPV did not. Therefore the use of BPZE1 should also have an impact on the incidence of whooping cough caused by *B. parapertussis* in infants.

[0121] Although the recent replacement of first generation whole-cell vaccines by new aPV in many countries has significantly reduced the systemic adverse reactions observed with whole-cell vaccines, it has not abolished the need for repeated vaccination to achieve protection. This makes it unlikely to obtain protection in very young children (<6 months) that present the highest risk to develop severe disease. In addition, the wide-spread use of aPV has revealed new, unforeseen problems. Repeated administration of aPV may cause extensive swelling at the site of injection [41], which was not observed with whole-cell vaccines. In approximately 5 % of the cases this swelling involves almost the entire limb and lasts for more than a week. Although the mechanism of this swelling has not been characterized yet, it has been proposed to be due to an Arthus hypersensitivity reaction caused by high antibody levels induced by the primary immunization [42]. However, it could also be related to the Th2 skewing of the immune response, as, compared to whole-cell vaccines, aPV administration induces more Th2-type cytokines in vaccinated children [10] and causes a delay in the Th1 development (Mascart *et al.*, in preparation). Delayed maturation of Th1 function has been associated with a risk for atopy in genetically pre-disposed individuals [33]. The two mechanisms are not mutually exclusive. Compared to aPV, the immune response to BPZE1 administration is less biased towards the Th2 arm, and since BPZE1 is administered mucosally, no swelling reaction can occur.

[0122] The use of live attenuated bacteria as vaccines raises the issue of their biosafety. As such, they fall under the directives and guidelines for genetically modified organisms susceptible to be released into the environment. These guidelines and directives describe several objectives that have to be met, including hazard identification and environmental risk assessment [44]. Potential pathogenicity needs to be carefully considered, especially in immuno-compromized individuals, such as those infected with HIV. The natural biology of *B. pertussis* is particularly interesting in that regard. Although pertussis in HIV-infected subjects has been described occasionally, it is rather rare in AIDS patients [45]. In its genetically attenuated form, *B. pertussis* would therefore not be expected to cause major problems in HIV-infected children, especially if severe AIDS is an exclusion criterion, as it is for many vaccines. *B. pertussis* colonization is strictly limited to the respiratory epithelium, without extrapulmonary dissemination of the bacteria, which naturally excludes systemic bacteremia of the BPZE1 vaccine strain. If nevertheless unforeseeable safety problems occurred, the vaccine strain can easily be eliminated by the use of macrolide antibiotics, such as erythromycin, to which essentially

all *B. pertussis* isolates are highly sensitive.

[0123] A further concern, like for any live vaccine, is the potential release of the vaccine strain in the environment and the consequences of such a release. *B. pertussis* is a strictly human pathogen, and there is no animal vector or reservoir. Moreover, unlike *B. bronchiseptica*, survival of wild-type *B. pertussis* in the environment is extremely limited [46]. *Pertussis* is only spread by coughing individuals, and there appears to be no asymptomatic carriage [47]. Coughing cannot be assessed in the mouse models used in this study. However, due to the nature of the genetic alterations in BPZE1, in particular the strong reduction of TCT and the genetic inactivation of PTX, this strain would not be expected to induce coughing. Active PTX has been shown to be required for cough induction in a coughing rat model, although the mechanism is not known [48]. If the vaccine strain were nevertheless to be transmitted to non-vaccinated individuals, this would at worst result in increased vaccine coverage. The consequences of each of these potential hazards can thus be graded as negligible and can easily and rapidly be controlled by antibiotic treatment if necessary.

[0124] Advantages of the use of BPZE1 include the relatively low production costs, making it especially attractive for developing countries, its needle-free easy and safe mode of administration and its potential to induce mucosal immunity in addition to systemic immunity. Although the role of mucosal immunity against *pertussis* has surprisingly not been much addressed, the fact that *B. pertussis* is a strictly mucosal pathogen, makes it likely that mucosal immune responses may contribute significantly to protection. None of the currently available vaccines induces any significant mucosal response.

[0125] Other advantages of the use of BPZE1 in vaccination are:

- the rapid protective immune response obtained after a single intranasal dose of BPZE1, since induction of the immunity can be detected 1 week after vaccination,
- an increase of the protective immunity over the at least next two months after vaccination, and
- the complete protective immunity, since a level of protection of more than 99.999% is obtained 2 weeks after vaccination.

[0126] The use of live attenuated *B. pertussis* for mucosal vaccination offers yet another advantage. *B. pertussis* can be used for the presentation of heterologous antigens to the respiratory mucosa (for review see 49). The use of BPZE1 as a heterologous expression platform may thus be helpful for the generation of multivalent vaccines against a variety of respiratory pathogens. However, since intranasal delivery of BPZE1 also induces strong systemic immune responses, as shown here by both the high levels of anti-FHA antibodies and of antigen-specific IFN- γ production, it may also be used for the production of antigens to which systemic immune responses are desired.

REFERENCES

[0127]

1. WHO (2004) The world health report 2004-changing history, Geneva, WHO.
2. Das P (2002) Whooping cough makes global comeback. *Lancet* ii: 322.
3. Tan T, Trindade E, Skowronski D (2005) Epidemiology of Pertussis. *Pediatr Infect Dis J* 24: S10-S18.
4. Centers for Disease Control and Prevention. Pertussis. Available : <http://www.cdc.gov/nip/publications/pink/pert.pdf> via the Internet.
5. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N (2002) Pertussis of adults and infants. *Lancet Infect Dis* 2: 744-750.
6. Lewis DB, Yu CC, Meyer J, English BK, Kahn SJ, et al. (1991) Cellular and molecular mechanisms for reduced interleukin-4 and interferon- γ production by neonatal T cells. *J Clin Invest* 87: 194-202.
7. Siegrist CA (2001) Neonatal and early life vaccinology. *Vaccine*. 19: 3331-3346.
8. Mills KHG (2001) Immunity to Bordetella pertussis. *Microbes Infect* 3: 655-677.
9. Lewis DB, Larsen A, Wilson CB (1986) Reduced interferon- γ mRNA levels in human neonates. *J Exp Med* 163: 1018-1023.
10. Ausiello CM, Urbani F, La Sala A, Lande R, Cassone A (1997) Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination in infants with whole-cell or acellular pertussis vaccines. *Infect Immun* 65: 2168-2174.
11. Wirsing von Konig CH, Postels-Multani S, Bock HL, Schmitt HJ (1995) Pertussis in adults : frequency of transmission after household exposure. *Lancet* 346: 1326-1329.
12. Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, et al. (2003) Bordetella pertussis infection in 2-months-old infants promotes Type 1 T cell responses. *J Immunol* 170: 1504-1509.
13. Menozzi FD, Mutombo R, Renaud G, Gantiez C, Hannah JH, et al. (1994) Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. *Infect Immun* 62: 769-778.

14. Imaizumi A, Suzuki Y, Ono S, Sato H, Sato Y (1983) Effect of heptakis (2,6-O-dimethyl)-beta-cyclodextrin on the production of pertussis toxin by *Bordetella pertussis*. *Infect Immun* 41: 1138-1143.
15. Cookson BT, Cho H-L, Herwaldt LA, Goldman WE (1989) Biological activities and chemical composition of purified tracheal cytotoxin of *Bordetella pertussis*. *Infect Immun* 57: 2223-2229.
- 5 16. Alonso S, Pethe K, Mielcarek N, Raze D, Locht C (2001) Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during *Bordetella pertussis* infection. *Infect Immun* 69: 6038-6043.
17. Collyn F, Lety MA, Nair S, Escuyer V, Ben Younes A, et al. (2002) *Yersinia pseudotuberculosis* harbors a type IV pilus gene cluster that contributes to pathogenicity. *Infect Immun* 70: 619-620.
- 10 18. Mielcarek N, Cornette J, Schacht AM, Pierce RJ, Locht C, et al. (1997) Intranasal priming with recombinant *Bordetella pertussis* for the induction of a systemic immune response against a heterologous antigen. *Infect Immun* 65: 544-550.
19. Locht C, Geoffroy MC, Renauld G (1992) Common accessory genes for the *Bordetella pertussis* filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. *EMBO J* 11: 3175-3183.
- 15 20. Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL (1983) Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. *J Biol Chem* 258: 14647-14651.
21. Antoine R, Locht C (1990) Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. *Infect Immun* 58: 1518-1526.
- 20 22. Menozzi FD, Gantiez C, Locht C (1991) Interaction of the *Bordetella pertussis* filamentous haemagglutinin with heparin. *FEMS Microbiol Lett* 62: 59-64.
23. Locht C, Antoine R, Jacob-Dubuisson F (2001) *Bordetella pertussis*, molecular pathogenesis under multiple aspects. *Curr Opin Microbiol* 4: 82-89.
24. Heiss LN, Flak TA, Lancaster JR, McDaniel ML, Goldman WE (1993) Nitric oxide mediates *Bordetella pertussis* tracheal cytotoxin damage to the respiratory epithelium. *Infect Agents Dis* 2: 173-177.
- 25 25. Goldman WE, Cookson BT (1988) Structure and functions of the *Bordetella* tracheal cytotoxin. *Tokai J Exp Clin Med* 13 Suppl: 187-191.
26. Locht C, Antoine R (1999) *Bordetella pertussis* protein toxins. In: Alouf JE, Freer JH, editors. *Comprehensive sourcebook of bacterial protein toxins*. Academic Press, pp. 130-146.
- 30 27. Guiso N, Capiou C, Carletti G, Poolman J, Hauser P (1999) Intranasal murine model of *Bordetella pertussis* infection. I. Prediction of protection in human infants by acellular vaccines. *Vaccine* 17: 2366-2376.
28. Mills KH, Ryan M, Ryan E, Mahon BP (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against *Bordetella pertussis*. *Infect Immun* 66: 594-602.
- 35 29. Roduit C, Bozzotti P, Mielcarek N, Lambert PH, Del Giudice G, et al. (2002) Immunogenicity and protective efficacy of neonatal immunization against *Bordetella pertussis* in a murine model: Evidence for early control of Pertussis. *Infect Immun* 70: 3521-3528.
30. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J (1998) Whooping cough caused by *Bordetella pertussis* and *Bordetella parapertussis* in an immunized population. *JAMA* 280: 635-637.
- 40 31. Watanabe M, Nagai M (2004) Whooping cough due to *Bordetella parapertussis*: an unresolved problem. *Expert Rev Anti Infect Ther* 2: 447-454.
32. Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, et al. (1998) *Bordetella parapertussis* infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. *J Clin Microbiol* 36: 999-1002.
- 45 33. Liese JG, Renner C, Stojanov S, Belohradsky BH, Munich Vaccine Study Group. (2003) Clinical and epidemiological picture of *B. pertussis* and *B. parapertussis* infections after introduction of acellular pertussis vaccines. *Arch Dis Child* 88: 684-687.
34. Watanabe M, Nagai M (2001) Reciprocal protective immunity against *Bordetella pertussis* and *Bordetella parapertussis* in a murine model of respiratory infection. *Infect Immun* 69: 6981-6986.
- 50 35. Locht C, Bertin P, Menozzi FD, Renauld G (1993) The filamentous haemagglutinin, a multifaceted adhesin produced by virulent *Bordetella* spp. *Mol Microbiol* 9: 653-660.
36. Huang CC, Chen PM, Kuo JK, Chui WH, Lin ST, et al. (1962) Experimental whooping cough. *N Engl J Med* 266: 105-111.
37. Bey RF, Shade FJ, Goodnow RA, Johnson RC (1981) Intranasal vaccination of dogs with live avirulent *Bordetella bronchiseptica*: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. *Am J Vet Res* 42: 1130-1132.
- 55 38. De Jong MF (1987) Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic *Bordetella bronchiseptica* vaccine. *Vet Q* 9: 123-133.

39. Hoiseth SK, Stocker BAD (1981) Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* 291: 238 - 239.
40. Roberts M, Maskell D, Novotny P, Dougan G (1990) Construction and characterization in vivo of *Bordetella pertussis* aroA mutants. *Infect Immun* 58: 732-739.
- 5 41. Rennels MB (2003) Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. *Semin Pediatr Infect Dis* 14: 196-198.
42. Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, et al. (2005) The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. *J Infect Dis* 191: 81-88.
- 10 43. Holt PG, Clough JB, Holt BJ, Baron-Hay MJU, Rose AH, et al. (1992) Genetic "risk" for atopy is associated with delayed postnatal maturation of T-cell competence. *Clin Exp Allergy* 22: 1093-1099.
44. Favre D, Viret JF (2006) Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. *Vaccine*. May 1;24(18):3856-64.
45. Cohn SE, Knorr KL, Gilligan PH, Smiley ML, Weber DJ (1993) Pertussis is rare in human immunodeficiency virus disease. *Am Rev Respir Dis* 147: 411-413.
- 15 46. Porter JF, Wardlaw AC (1993) Long-term survival of *Bordetella bronchiseptica* in lakewater and in buffered saline without added nutrients. *FEMS Microbiol Lett* 110: 33-36.
47. Linnemann CCJr, Bass JW, Smith MHD (1968) The carrier state in pertussis. *Am J Epidemiol* 88: 422-427.
48. Parton R, Hall E, Wardlaw AC (1994) Responses to *Bordetella pertussis* mutant strains and to vaccination in the coughing rat model of pertussis. *J Med Microbiol* 40: 307-312.
- 20 49. Mielcarek N, Alonso S, Loch C (2001) Nasal vaccination using live bacterial vectors. *Adv Drug Del Rev* 51: 55-69.
50. Lyon RS, Engle JT, Goldman WE. Manuscript in preparation
51. Simon R, Priefer U, Pühler A (1983) A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. *Bio/Technology* 1: 784-791.
- 25 52. Stibitz S (1994) Use of conditionally counterselectable suicide vectors for allelic exchange. *Methods Enzymol* 235: 458-465.
53. Antoine R, Huvent I, Chemlal K, Deray I, Raze D, et al. (2005) The periplasmic binding protein of tripartite tricarboxylate transporter is involved in signal transduction. *J Mol Biol* 351: 799-809.
54. Sato H, Ito A, Chiba J, Sato Y (1984) Monoclonal antibodies against pertussis toxin: effect on toxin activity and pertussis infections. *Infect Immun* 46: 422-428.
- 30 55. Sato H, Sato Y, Ito A, Ohishi I (1987) Effect of monoclonal antibody to pertussis toxin on toxin activity. *Infect Immun* 55: 909-915.
56. Tuomanen, E. And Weiss A. (1985) Characterization of two adhesions of *Bordetella pertussis* for human ciliated respiratory epithelial cells. *J. Infect. Dis.* 152:118-125.
- 35 57. Loch, C., Antoine, R., Veithen A. and Raze D. 2000. Pertussis Toxin: Structure-Function-Relationship. In Aktories K. Just I editors. *Handbook of Experimental Pharmacology, Bacterial Protein Toxins*, Springer, vol 145, pp. 167-185.
58. Horiguchi Y, Matsuda, H. Koyama H, Nakai T and Kume K. (1992) *Bordetella bronchiseptica* dermonecrotizing toxin suppresses in vivo antibody responses in mice. *FEMS Microbiol. Lett.* 69:229-234.
59. Bordet et Genysa (1909) L'endotoxine coquelucheuse ; *Ann. Inst. Pasteur* 23 : 415-419.
- 40 60. Iida & Okonogi (1971) Lipo toxicity of *Bordetella pertussis* in mice ; *J. Med. Microbiol.* 4: 51-61.
61. R. Parton (1985) Effect of prednisone on the toxicity of *Bordetella pertussis* in mice, *J. Med. Microbiol.* 19: 391-400.
62. Magyar et al (1988) The pathogenesis of turbinate atrophy in pigs caused by *Bordetella bronchiseptica*, *Vet. Microbiol.* 3 : 1719-1728.
63. Roop et al (1987) Virulence factors of *Bordetella bronchiseptica* associated with the production of infectious atrophic rhinitis and pneumonia in experimentally infected neonatal swine, *Infect. Immun.* 55 : 217-222.
- 45 64. Weiss & Goodman (1989) Lethal infection by *Bordetella pertussis* mutants in the infant mouse model, *Infect. Immun.* 57 : 3757-3764.
65. Allan & Maskell (1996) The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in *Bordetella pertussis*, *Mol. Microbiol.* 19 : 37-52.
- 50 66. Alonso et al (2002) Eighty kilodalton N-terminal moiety of *Bordetella pertussis* filamentous hemagglutinin: adherence, immunogenicity, and protective role, *Infection & Immunity*, 70, 4142-4147.
67. Cummings, C.A., Bootsma, H.J., Relman D.A. and Miller J.F. (2006) Species- and Strain-specific Control of a Complex, Flexible Regulon by *Bordetella BvgAS*. *J. Bacteriol.* 188:1775-1785.
68. Kashimoto T., Katahira J, Cornejo WR, Masuda M, Fukuoh A, Matsuzawa T, Ohnishi T, Horiguchi Y. (1999) Identification of functional domains of *Bordetella dermonecrotizing* toxin. *Infect. Immun.* 67(8) 3727-32.
- 55

Claims

1. A vaccine comprising a live, attenuated mutated *Bordetella pertussis* strain comprising at least a mutated *pertussis* toxin (*ptx*) gene which codes for an enzymatically inactive pertussis toxin (PTX), a deleted dermonecrotic toxin (*dnt*) gene or a mutated *dnt* gene that codes for an enzymatically inactive dermonecrotic toxin (DNT), and a heterologous *ampG* gene which replaces the *Bordetella ampG* gene, and a pharmaceutically suitable excipient, vehicle and/or carrier, wherein the strain is able to colonize and induce protective immunity in a subject, wherein the replacement of the *Bordetella ampG* gene with the heterologous *ampG* gene causes the *Bordetella pertussis* strain to express less than 5% of the tracheal cytotoxin (TCT) activity as that expressed by a *Bordetella pertussis* strain which does not have its native *ampG* gene replaced with the heterologous *ampG* gene.
2. The vaccine according to claim 1, wherein the *Bordetella ampG* gene is replaced by an *Escherichia coli ampG* gene, a *Salmonella ampG* gene, an *Enterobacteriaceae ampG* gene, a *Pseudomonas ampG* gene, a *Moraxella ampG* gene, a *Helicobacter ampG* gene, a *Stenotrophomonas ampG* gene, or a *Legionella ampG* gene.
3. The vaccine according to claim 1 or 2, wherein the replacement of the *Bordetella ampG* gene with the heterologous *ampG* gene causes the *Bordetella pertussis* strain to express less than 1% of the tracheal cytotoxin (TCT) activity as that expressed by a *Bordetella pertussis* strain which does not have its native *ampG* gene replaced with the heterologous *ampG* gene.
4. The vaccine according to any one of claims 1 to 3, wherein said mutated *Bordetella pertussis* strain comprises a deleted *dnt* gene.
5. The vaccine according to any one of claims 1 to 4, wherein said mutated *Bordetella pertussis* strain comprises a mutated *dnt* gene coding for an enzymatically-inhibited protein, and wherein said mutated *dnt* gene is mutated by point mutation or by insertion of a genetic sequence or plasmid interrupting the open reading frame of the *dnt* gene.
6. The vaccine according to any one of claims 1 to 5, which is for intranasal administration or inhalation.
7. The vaccine according to any one of claims 1 to 6, which is a vaccine against infections caused by *Bordetella* species.
8. The vaccine according to claim 7, which is a prophylaxis vaccine against infections caused by *Bordetella* species.
9. The vaccine according to claim 7 or 8, wherein the *Bordetella* species is *B. pertussis* or *B. parapertussis*.
10. The vaccine according to any one of claims 1 to 9, which is for administration to mammals in need of a rapid protective immunity against a *Bordetella* infection.
11. The vaccine according to any one of claims 1 to 10, which is for administration to newborns or to adults over the age of 60.

Patentansprüche

1. Impfstoff, umfassend einen lebenden, abgeschwächten, mutierten *Bordetella pertussis*-Stamm, umfassend mindestens ein mutiertes *PertussisToxin- (ptx)* Gen, das für ein enzymatisch inaktives Pertussistoxin (PTX) codiert, ein deletiertes dermonekrotisches Toxin- (*dnt*) Gen oder ein mutiertes *dnt*-Gen, das für ein enzymatisch inaktives dermonekrotisches Toxin (DNT) codiert, und ein heterologes *ampG*-Gen, das das *Bordetella ampG*-Gen ersetzt, und ein pharmazeutisch geeignetes Excipiens, Vehikel und/oder einen pharmazeutisch geeigneten Träger, wobei der Stamm imstande ist, in einem Subjekt zu kolonisieren und eine schützende Immunität hervorzurufen, wobei das Ersetzen des *Bordetella ampG*-Gens mit dem heterologen *ampG*-Gen den *Bordetella pertussis*-Stamm veranlasst, weniger als 5 % der trachealen Cytotoxin- (TCT) Aktivität zu exprimieren als durch einen *Bordetella pertussis*-Stamm exprimiert wird, dessen natives *ampG*-Gen nicht mit dem heterologen *ampG*-Gen ersetzt ist.
2. Impfstoff nach Anspruch 1, wobei das *Bordetella ampG*-Gen durch ein *Escherichia coli ampG*-Gen, ein *Salmonella ampG*-Gen, ein *Enterobacteriaceae ampG*-Gen, ein *Pseudomonas ampG*-Gen, ein *Moraxella ampG*-Gen, ein *Helicobacter ampG*-Gen, ein *Stenotrophomonas ampG*-Gen oder ein *Legionella ampG*-Gen ersetzt ist.

3. Impfstoff nach Anspruch 1 oder 2, wobei das Ersetzen des *Bordetella* ampG-Gens mit dem heterologen ampG-Gen den *Bordetella pertussis*-Stamm veranlasst, weniger als 1 % der trachealen Cytotoxin- (TCT) Aktivität zu exprimieren als jene, die durch einen *Bordetella pertussis*-Stamm exprimiert wird, dessen natives ampG-Gen nicht mit dem heterologen ampG-Gen ersetzt ist.
4. Impfstoff nach einem der Ansprüche 1 bis 3, wobei der mutierte *Bordetella pertussis* Stamm ein deletiertes *dnt*-Gen umfasst.
5. Impfstoff nach einem der Ansprüche 1 bis 4, wobei der mutierte *Bordetella pertussis*-Stamm ein mutiertes *dnt*-Gen umfasst, das für ein enzymatisch inhibiertes Protein codiert, und wobei das mutierte *dnt*-Gen durch Punktmutation oder durch Einfügen einer genetischen Sequenz oder eines Plasmids, die bzw. das den offenen Leserahmen des *dnt*-Gens unterbricht, mutiert ist.
6. Impfstoff nach einem der Ansprüche 1 bis 5, der zur intranasalen Verabreichung oder Inhalation dient.
7. Impfstoff nach einem der Ansprüche 1 bis 6, der ein Impfstoff gegen Infektionen ist, die durch Bordetella-Gattung verursacht werden.
8. Impfstoff nach Anspruch 7, der ein Prophylaxe-Impfstoff gegen Infektionen ist, die durch Bordetella-Gattung verursacht werden.
9. Impfstoff nach Anspruch 7 oder 8, wobei die *Bordetella* Gattung *B. pertussis* oder *B. parapertussis* ist.
10. Impfstoff nach einem der Ansprüche 1 bis 9, der zur Verabreichung an Säugetiere dient, die eine rasche schützende Immunität gegen eine *Bordetella*-Infektion benötigen.
11. Impfstoff nach einem der Ansprüche 1 bis 10, der zur Verabreichung an Neugeborene oder Erwachsene im Alter über 60 Jahren dient.

Revendications

1. Vaccin comprenant une souche de *Bordetella pertussis* atténuée et mutée comprenant au moins un gène de toxine pertussique muté (*ptx*) qui code pour une toxine pertussique enzymatiquement inactive (PTX), un gène de toxine dermonécrotique (*dnt*) délété ou un gène *dnt* muté qui code pour une toxine dermonécrotique (DNT) enzymatiquement inactive, et un gène *ampG* hétérologue qui remplace le gène *ampG* de *Bordetella*, et un excipient pharmaceutiquement approprié, un véhicule et/ou un transporteur, dans lequel la souche est capable de coloniser et d'induire une immunité protectrice chez un sujet, dans lequel le remplacement du gène *ampG* de *Bordetella* par le gène *ampG* hétérologue entraîne la souche de *Bordetella pertussis* à exprimer moins de 5% de l'activité de la cytotoxine trachéale (TCT) telle qu'exprimée par la souche *Bordetella pertussis* qui n'a pas son gène *ampG* natif remplacé par le gène *ampG* hétérologue.
2. Vaccin selon la revendication 1, dans lequel le gène *ampG* de *Bordetella* est remplacé par un gène *ampG* d'*Escherichia coli*, un gène *ampG* de *Salmonella*, un gène *ampG* d'*Enterobacteriaceae*, un gène *ampG* de *Pseudomonas*, un gène *ampG* de *Moraxella*, un gène *ampG* d'*Helicobacter*, un gène *ampG* de *Stenotrophomonas*, ou un gène *ampG* de *Legionella*.
3. Vaccin selon la revendication 1 ou 2, dans lequel le remplacement du gène *ampG* de *Bordetella* par le gène *ampG* hétérologue entraîne la souche *Bordetella pertussis* à exprimer moins de 1% de l'activité de la cytotoxine trachéale (TCT) telle qu'exprimée par la souche *Bordetella pertussis* qui n'a pas son gène *ampG* natif remplacé par le gène *ampG* hétérologue.
4. Vaccin selon l'une quelconque des revendications 1 à 3, dans lequel ladite souche mutée de *Bordetella pertussis* comprend un gène *dnt* délété.
5. Vaccin selon l'une quelconque des revendications 1 à 4, dans lequel ladite souche mutée de *Bordetella pertussis* comprend un gène *dnt* muté codant pour une protéine enzymatiquement inhibée, et dans laquelle ledit gène *dnt* muté est muté par mutation ponctuelle ou par insertion d'une séquence génétique ou d'un plasmide interrompant

le cadre ouvert de lecture du gène *dnt*.

6. Vaccin selon l'une quelconque des revendications 1 à 5, pour son administration intranasale ou son inhalation.
- 5 7. Vaccin selon l'une quelconque des revendications 1 à 6, qui est un vaccin contre les infections causées par les espèces de *Bordetella*.
8. Vaccin selon la revendication 7, qui est un vaccin prophylactique contre des infections causées par les espèces de *Bordetella*.
- 10 9. Vaccin selon la revendication 7 ou 8, dans lequel les espèces de *Bordetella* sont *B. pertussis* ou *B. parapertussis*.
10. Vaccin selon l'une quelconque des revendications 1 à 9, pour son administration à des mammifères ayant besoin d'une immunité protectrice rapide contre une infection par *Bordetella*.
- 15 11. Vaccin selon l'une quelconque des revendications 1 à 10, pour son administration à des nouveau-nés ou aux adultes de plus de 60 ans.

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

Islet-activating protein S1 (NP_882282)

MRCTRAIRQTARTGWLTWLAILAVTAPVTSPAWADDPPATVYRYDSRPPEDVF
QNGFTAWGNNDNVLDHLTGRSCQVGSSNSAFVSTSSSSRRYTEVYLEHRMQEAV
EAERAGRGTGHFIGYIYEVRADNNFYGAASSYFEYVDITYGDNAGRILAGALAT
YQSEYLAHRRIIPPENIRRVTRVYHNGITGETTTTEYSNARYVSQQTRANPNPY
TSRRSVASIVGTLVRMAPVIGACMARQAESSEAMAAWSEAGEAMVLVYYESI
AYSF

Fig. 11

Dermonecrotic toxin (NP_881965)

MDKDESALRQLVDMALVGYDGVVEELLALPSEESGDLAGGRAKREKAEFALFS
 EAPNGDEPIGQDARTWFYFPKYRPVAVSNLKKMQVAIRARLEPESLILQWLIA
 LDVYLGVLIAALSRTVISDLVFEYVKARYEIIYYLLNRVPHPLATAYLKRRRQR
 PVDRSGRLGSVFEHPLWFAYDELAGTVDLADADIYEQALAESIERMDGEPDDG
 SLDTAEHVDWRLCRDGINRGEQAI FQASGPYGVVADAGYMR TVADLAYADALA
 DCLHAQLRIRAQGSVDSPGDEMPRKLD AWEI AKFH LAATQQARVDLLEAAFAL
 DYAAALRDVRVYGDYRNALALRFIKREALRLLGARRGNASTMPAVAAGEYDEIV
 ASGAANDAAVVSMAAALIAGVLC DLESAQRTLPVVLARFRPLGVLARFRRL EQ
 ETAGMLLG DQEPEPRGFISFTDFRDSDAFASYAEYAAQFNDYIDQYSILEAQR
 LARILALGSRMTVDQWCLPLQKVRHYKVLTSQPGLIARGIENHNRGIEYCLGR
 PPLTDLPGLFTMFQLHDSSWLLVSNINGELWSDVLANA EVMQNPTLAALAE PQ
 GRFRTGRRTGGWFLGGPATEGPSLRDNYLLKLRQSNPGLDVKKCWYFGYRQEY
 RLPAGALGVPLFAVSVALRHS LDDLA AHAKSALYKPSEWQKFAFWIVPFYREI
 FFSTQDRSYRVDVGSIVFDSISLLASVFSIGGKLGSFTRTQYGNLRNFVVRQR
 IAGLSGQRLWRSVLKELPALIGASGLRLSRSLLDLYEIFEVPPIRRLVAGFV
 SATTVGGRNQAF LRQA FSAASSSAGRTGGQLASEWRMAGVDATGLVESTSGGR
 FEGIIYTRGLGPLSECTEHFIVESGNAYRVIW DAYTHGWRVVNGRLPPRLTYTV
 PVRLNGQGHWETHLDVPGRGGAPEIFGRIRTRNLVALAAEQAAPMRLLNQAR
 RVALRHIDTCRSRLALPRAESDMDAAIRIFFGE PDAGLRQRI GRRLQEV RAYI
 GDLSPVNDVLYRAGYDLDDVATLFNAVDRNTSLGRQARMELYLD AIVDLHARL
 GYENARFVDLMAFHLLSLGHAATASEVVEAVSPRLLGNVFDISNVAQLERGIG
 NPASTGLFVMLGAYSESSPAIFQS FVNDIFPAWRQASGGGPLVWNFGPAAISP
 TRLDYANTDIGLLNHGDISPLRARPP LGGRRDIDLPPGLDISFVRYDRPVRMS
 APRALDASVFRPVDGPVHG YIQSWTGAEIEYAYGAPAAAREVMLTDNVRIISI
 ENGDEGAIGVRVRLDTVPVATPLILTGGSLSGCTTMVGVKEGYLAFYHTGKST
 ELGDWATAREGVQALYQAHLAMGYAPISIPAPMRNDDLVSIAATYDRAVIAYL
 GKDVPGGGSTRITRHDEGAGSVVSFDYNAAVQASAVPRLGQVYVLISNDGQGA
 RAVLLAEDLAWAGSGSALDVLNERLVTLPAPV

Fig. 12

AmpG protein (NP_878961.1)

MAPLLVLGFASGLPLALSSGTLQAWATVENVSLQSIGFLTLAGTAYTLKFLWA
PLIDRYVPPFLGRRRGWMLLTQVLLAAAIMVMGMLSPPGSALLPLALVAVLVAF
LSASQDIAFDAYSTDVLRQEERGAGAAMRVMGYRLAMIVSGGLALIVADRWLG
WGNTYVLMGGLMLACALGTLWAPERPERPANPPRDLGAAVVEPFREFFSRRGAI
DMLLLIVLYKLGDFAFAGALSTTFLLRGAGFSATEVGTVNKVLGLAATIVGALA
GGSIMTRWGLYRSLMAFGLLQAVSNLGYWLI AVSPKNLYLMGLAVGVENLCGG
LGTASFVALLMAMCRQQFSATQFALLSALA AVGRTYLAGPLTPVLVEWLDWPG
FFIVTVLIALPGLWLLRLRRNVIDELDAQTAR

Fig. 13

AmpG protein (NP_752478.1)

MSSQYLRI FQQPRSA ILLILGFASGLPLALTSGTLQAWMTVENIDLKTIGFFS
LVGQAYVFKFLWSPLMDRYTPPFFGRRRGWLLATQILLLV AIAAMGFLEPGTQ
LRWMAALAVVIAFCSASQDIVFD AWKTDVLP AEERGAGAAISVLGYRLGMLVS
GGLALWLADKWLGWQGM YWLMAALLIPCI IATLLAPEPTDTIPVPKTLEQAVV
APLRDFFGRNNAWLILL LVLVLYKLGD AFAMSLTTTFLIRGVGFDAGEVG VVNK
TLG LLATIVGALYGGILMQRLSLFRALLIFGILQGASNAGYWLLSITDKHLYS
MGA AVFFENLCGGMGTS AFVALMTLCNKSF SATQFALLSALS AVGRVYVGPV
AGWFVEAHGWSTFYLF SVAAAVPGLILL LVCRQTLEYTRVNDNFISRTEYPAG
YAFAMWTLAAGISLLAVW LLLL TMDALDLTHFSFLPALLEVGV LVALS GVVLG
GLLDYLALRKTHLM

Fig. 14

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- FR 0206666 [0007]
- US 6713072 B [0059]

Non-patent literature cited in the description

- MIELCAREK et al. *Vaccine*, 2006, vol. 24S2, S2, , 54-S2, 55 [0008]
- MIELCAREK et al. *Advance Drug Delivery Review*, 2001, vol. 51, 55-69 [0009]
- RODUIT et al. *Infection and Immunity*, July 2002, vol. 70 (7), 3521-8 [0010]
- MATTOO et al. *Frontiers of Bioscience*, 2001, vol. 6, e168-e186 [0011]
- TAN T ; TRINDADE E ; SKOWRONSKI D. Epidemiology of Pertussis. *Pediatr Infect Dis J*, 2005, vol. 24, S10-S18 [0127]
- WIRSING VON KONIG CH ; HALPERIN S ; RIF-FELMANN M ; GUISON N. Pertussis of adults and infants. *Lancet Infect Dis*, 2002, vol. 2, 744-750 [0127]
- LEWIS DB ; YU CC ; MEYER J ; ENGLISH BK ; KAHN SJ et al. Cellular and molecular mechanisms for reduced interleukin-4 and interferon- γ production by neonatal T cells. *J Clin Invest*, 1991, vol. 87, 194-202 [0127]
- SIEGRIST CA. Neonatal and early life vaccinology. *Vaccine*, 2001, vol. 19, 3331-3346 [0127]
- MILLS KHG. Immunity to Bordetella pertussis. *Microbes Infect*, 2001, vol. 3, 655-677 [0127]
- LEWIS DB ; LARSEN A ; WILSON CB. Reduced interferon- γ mRNA levels in human neonates. *J Exp Med*, 1986, vol. 163, 1018-1023 [0127]
- AUSIELLO CM ; URBANI F ; LA SALA A ; LANDE R ; CASSONE A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination in infants with whole-cell or acellular pertussis vaccines. *Infect Immun*, 1997, vol. 65, 2168-2174 [0127]
- WIRSING VON KONIG CH ; POSTELS-MULTANI S ; BOCK HL ; SCHMITT HJ. Pertussis in adults : frequency of transmission after household exposure. *Lancet*, 1995, vol. 346, 1326-1329 [0127]
- MASCART F ; VERSCHURE V ; MALFROOT A ; HAINAUT M ; PIÉRARD D et al. Bordetella pertussis infection in 2-months-old infants promotes Type 1 T cell responses. *J Immunol*, 2003, vol. 170, 1504-1509 [0127]
- MENOZZI FD ; MUTOMBOR ; RENAULD G ; GANTIEZ C ; HANNAH JH et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. *Infect Immun*, 1994, vol. 62, 769-778 [0127]
- IMAIZUMI A ; SUZUKI Y ; ONO S ; SATO H ; SATO Y. Effect of heptakis (2,6-O-dimethyl)-beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis. *Infect Immun*, 1983, vol. 41, 1138-1143 [0127]
- COOKSON BT ; CHO H-L ; HERWALDT LA ; GOLDMAN WE. Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. *Infect Immun*, 1989, vol. 57, 2223-2229 [0127]
- ALONSO S ; PETHE K ; MIELCAREK N ; RAZE D ; LOCHT C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. *Infect Immun*, 2001, vol. 69, 6038-6043 [0127]
- COLLYN F ; LETY MA ; NAIR S ; ESCUYER V ; BEN YOUNES A et al. Yersinia pseudotuberculosis harbors a type IV pilus gene cluster that contributes to pathogenicity. *Infect Immun*, 2002, vol. 70, 619-620 [0127]
- MIELCAREK N ; CORNETTE J ; SCHACHT AM ; PIERCE RJ ; LOCHT C et al. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. *Infect Immun*, 1997, vol. 65, 544-550 [0127]
- LOCHT C ; GEOFFROY MC ; RENAULD G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. *EMBO J*, 1992, vol. 11, 3175-3183 [0127]
- SEKURA RD ; FISH F ; MANCLARK CR ; MEADE B ; ZHANG YL. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. *J Biol Chem*, 1983, vol. 258, 14647-14651 [0127]
- ANTOINE R ; LOCHT C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. *Infect Immun*, 1990, vol. 58, 1518-1526 [0127]

- **MENOZZI FD ; GANTIEZ C ; LOCHT C.** Interaction of the *Bordetella pertussis* filamentous haemagglutinin with heparin. *FEMS Microbiol Lett*, 1991, vol. 62, 59-64 [0127]
- **LOCHT C ; ANTOINE R ; JACOB-DUBUISSON F.** *Bordetella pertussis*, molecular pathogenesis under multiple aspects. *Curr Opin Microbiol*, 2001, vol. 4, 82-89 [0127]
- **HEISS LN ; FLAK TA ; LANCASTER JR ; MCDANIEL ML ; GOLDMAN WE.** Nitric oxide mediates *Bordetella pertussis* tracheal cytotoxin damage to the respiratory epithelium. *Infect Agents Dis*, 1993, vol. 2, 173-177 [0127]
- **GOLDMAN WE ; COOKSON BT.** Structure and functions of the *Bordetella* tracheal cytotoxin. *Tokai J Exp Clin Med*, 1988, vol. 13, 187-191 [0127]
- *Bordetella pertussis* protein toxins. **LOCHT C ; ANTOINE R.** Comprehensive sourcebook of bacterial protein toxins. Academic Press, 1999, 130-146 [0127]
- **GUISO N ; CAPIAU C ; CARLETTI G ; POOLMAN J ; HAUSER P.** Intranasal murine model of *Bordetella pertussis* infection. I. Prediction of protection in human infants by acellular vaccines. *Vaccine*, 1999, vol. 17, 2366-2376 [0127]
- **MILLS KH ; RYAN M ; RYAN E ; MAHON BP.** A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against *Bordetella pertussis*. *Infect Immun*, 1998, vol. 66, 594-602 [0127]
- **RODUIT C ; BOZZOTTI P ; MIELCAREK N ; LAMBERT PH ; DEL GIUDICE G et al.** Immunogenicity and protective efficacy of neonatal immunization against *Bordetella pertussis* in a murine model: Evidence for early control of Pertussis. *Infect Immun*, 2002, vol. 70, 3521-3528 [0127]
- **HE Q ; VILJANEN MK ; ARVILOMMI H ; AITTANEN B ; MERTSOLA J.** Whooping cough caused by *Bordetella pertussis* and *Bordetella parapertussis* in an immunized population. *JAMA*, 1998, vol. 280, 635-637 [0127]
- **WATANABE M ; NAGAI M.** Whooping cough due to *Bordetella parapertussis*: an unresolved problem. *Expert Rev Anti Infect Ther*, 2004, vol. 2, 447-454 [0127]
- **MASTRANTONIO P ; STEFANELLI P ; GIULIANO M ; HERRERA ROJAS Y ; CIOFI DEGLI ATTI M et al.** *Bordetella parapertussis* infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. *J Clin Microbiol*, 1998, vol. 36, 999-1002 [0127]
- Clinical and epidemiological picture of *B. pertussis* and *B. parapertussis* infections after introduction of acellular pertussis vaccines. **LIESE JG ; RENNER C ; STOJANOV S ; BELOHRADSKY BH.** Arch Dis Child. Munich Vaccine Study Group, 2003, vol. 88, 684-687 [0127]
- **WATANABE M ; NAGAI M.** Reciprocal protective immunity against *Bordetella pertussis* and *Bordetella parapertussis* in a murine model of respiratory infection. *Infect Immun*, 2001, vol. 69, 6981-6986 [0127]
- **LOCHT C ; BERTIN P ; MENOZZI FD ; RENAULD G.** The filamentous haemagglutinin, a multifaceted adhesin produced by virulent *Bordetella* spp. *Mol Microbiol*, 1993, vol. 9, 653-660 [0127]
- **HUANG CC ; CHEN PM ; KUO JK ; CHUI WH ; LIN ST et al.** Experimental whooping cough. *N Engl J Med*, 1962, vol. 266, 105-111 [0127]
- **BEY RF ; SHADE FJ ; GOODNOW RA ; JOHNSON RC.** Intranasal vaccination of dogs with live avirulent *Bordetella bronchiseptica*: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. *Am J Vet Res*, 1981, vol. 42, 1130-1132 [0127]
- **DE JONG MF.** Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic *Bordetella bronchiseptica* vaccine. *Vet Q*, 1987, vol. 9, 123-133 [0127]
- **HOISETH SK ; STOCKER BAD.** Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature*, 1981, vol. 291, 238-239 [0127]
- **ROBERTS M ; MASKELL D ; NOVOTNY P ; DOUGAN G.** Construction and characterization in vivo of *Bordetella pertussis* *aroA* mutants. *Infect Immun*, 1990, vol. 58, 732-739 [0127]
- **RENNELS MB.** Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. *Semin Pediatr Infect Dis*, 2003, vol. 14, 196-198 [0127]
- **ROBBINS JB ; SCHNEERSON R ; TROLLFORS B ; SATO H ; SATO Y et al.** The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. *J Infect Dis*, 2005, vol. 191, 81-88 [0127]
- **HOLT PG ; CLOUGH JB ; HOLT BJ ; BARON-HAY MJU ; ROSE AH et al.** Genetic "risk" for atopy is associated with delayed postnatal maturation of T-cell competence. *Clin Exp Allergy*, 1992, vol. 22, 1093-1099 [0127]
- **FAVRE D ; VIRET JF.** Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. *Vaccine*, 01 May 2006, vol. 24 (18), 3856-64 [0127]
- **COHN SE ; KNORR KL ; GILLIGAN PH ; SMILEY ML ; WEBER DJ.** Pertussis is rare in human immunodeficiency virus disease. *Am Rev Respir Dis*, 1993, vol. 147, 411-413 [0127]
- **PORTER JF ; WARDLAW AC.** Long-term survival of *Bordetella bronchiseptica* in lakewater and in buffered saline without added nutrients. *FEMS Microbiol Lett*, 1993, vol. 110, 33-36 [0127]

- LINNEMANN CCJR ; BASS JW ; SMITH MHD. The carrier state in pertussis. *Am J Epidemiol*, 1968, vol. 88, 422-427 [0127]
- PARTON R ; HALL E ; WARDLAW AC. Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis. *J Med Microbiol*, 1994, vol. 40, 307-312 [0127]
- MIELCAREK N ; ALONSO S ; LOCHT C. Nasal vaccination using live bacterial vectors. *Adv Drug Del Rev*, 2001, vol. 51, 55-69 [0127]
- LYONS ; ENGLE JT ; GOLDMAN WE. *Manuscript in preparation* [0127]
- SIMON R ; PRIEFER U ; PÜHLER A. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. *Bio/Technology*, 1983, vol. 1, 784-791 [0127]
- STIBITZ S. Use of conditionally counterselectable suicide vectors for allelic exchange. *Methods Enzymol*, 1994, vol. 235, 458-465 [0127]
- ANTOINE R ; HUVENT I ; CHEMLAL K ; DERAY I ; RAZE D et al. The periplasmic binding protein of tripartite tricarboxylate transporter is involved in signal transduction. *J Mol Biol*, 2005, vol. 351, 799-809 [0127]
- SATO H ; ITO A ; CHIBA J ; SATO Y. Monoclonal antibodies against pertussis toxin: effect on toxin activity and pertussis infections. *Infect Immun*, 1984, vol. 46, 422-428 [0127]
- SATO H ; SATO Y ; ITO A ; OHISHI I. Effect of monoclonal antibody to pertussis toxin on toxin activity. *Infect Immun*, 1987, vol. 55, 909-915 [0127]
- TUOMANEN, E. ; WEISS A. Characterization of two adhesions of Bordetella pertussis for human ciliated respiratory epithelial cells. *J. Infect. Dis.*, 1985, vol. 152, 118-125 [0127]
- Pertussis Toxin: Structure-Function-Relationship. LOCHT, C. ; ANTOINE, R. ; VEITHEN A. ; RAZE D. Handbook of Experimental Pharmacology, Bacterial Protein Toxins. Springer, 2000, vol. 145, 167-185 [0127]
- HORIGUCHI Y ; MATSUDA, H. ; KOYAMA H ; NAKAI T ; KUME K. Bordetella bronchiseptica dermonecrotizing toxin suppresses in vivo antibody responses in mice. *FEMS Microbiol. Lett.*, 1992, vol. 69, 229-234 [0127]
- BORDET ; GENYSA. L'endotoxine coquelucheuse. *Ann. Inst. Pasteur*, 1909, vol. 23, 415-419 [0127]
- LIDA ; OKONOGLI. Lipo toxicity of Bordetella pertussis in mice. *J. Med. Microbiol.*, 1971, vol. 4, 51-61 [0127]
- R. PARTON. Effect of prednisone on the toxicity of Bordetella pertussis in mice. *J. Med. Microbiol.*, 1985, vol. 19, 391-400 [0127]
- MAGYAR et al. The pathogenesis of turbinate atrophy in pigs caused by Bordetella bronchiseptica. *Vet. Microbiol.*, 1988, vol. 3, 1719-1728 [0127]
- ROOP et al. Virulence factors of Bordetella bronchiseptica associated with the production of infectious atrophic rhinitis and pneumonia in experimentally infected neonatal swine. *Infect. Immun.*, 1987, vol. 55, 217-222 [0127]
- WEISS ; GOODMAN. Lethal infection by Bordetella pertussis mutants in the infant mouse model. *Infect. Immun.*, 1989, vol. 57, 3757-3764 [0127]
- ALLAN ; MASKELL. The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in Bordetella pertussis. *Mol. Microbiol.*, 1996, vol. 19, 37-52 [0127]
- ALONSO et al. Eighty kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. *Infection & Immunity*, 2002, vol. 70, 4142-4147 [0127]
- CUMMINGS, C.A. ; BOOTSMA, H.J. ; RELMAN D.A. ; MILLER J.F. Species- and Strain-specific Control of a Complex, Flexible Regulon by Bordetella. *BvgAS.J. Bacteriol.*, 2006, vol. 188, 1775-1785 [0127]
- KASHIMOTO T. ; KATAHIRA J ; CORNEJO WR ; MASUDA M ; FUKUOKA ; MATSUZAWA T ; OHNISHI T ; HORIGUCHI Y. Identification of functional domains of Bordetella dermonecrotizing toxin. *Infect. Immun.*, 1999, vol. 67 (8), 3727-32 [0127]